

dis hist

(FILE 'HOME' ENTERED AT 10:30:14 ON 30 JAN 2007)

FILE 'REGISTRY' ENTERED AT 10:30:29 ON 30 JAN 2007

L1 STRUCTURE UPLOADED
L2 23 S L1 SSS SAM
L3 450 .S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:31:58 ON 30 JAN 2007

L4 0 S L3 AND (GEM(A)DIFLUORO)
L5 0 S L3 AND DIFLUORO
L6 1 S L3 AND ZINC
L7 0 S L3 AND REFORMATSKY
L8 44 S L3 AND (PROCESS OR PREPARA?)
L9 2 S L8 AND CARBONYL
L10 0 S L8 AND (CARBONYL(W)ADDITION)

Connecting via Winsock to STN

LOGINID:

sssptal623kxg

STNLOGON timed out

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal623kxg

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/Caplus F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/Caplus to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/Caplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/Caplus patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/Caplus accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/Caplus enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/Caplus Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/Caplus updated with revised CAS roles
NEWS	23	JAN 22	CA/Caplus enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:30:14 ON 30 JAN 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:30:29 ON 30 JAN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JAN 2007 HIGHEST RN 918776-45-1

DICTIONARY FILE UPDATES: 29 JAN 2007 HIGHEST RN 918776-45-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>


Uploading C:\Program Files\Stnexp\Queries\10522365-3.str

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 10:30:56 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 29 TO ITERATE

100.0% PROCESSED 29 ITERATIONS

23 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 257 TO 903

PROJECTED ANSWERS: 173 TO 747

L2 23 SEA SSS SAM L1

=> d scan


L2 23 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN L-Tryptophan, N2-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-arginyl-L-tryptophyl-L-tyrosyl- (9CI)

SQL 4

MF C45 H55 N9 O12

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 23 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Butanoic acid, 4-[[[(3,7-anhydro-2-deoxy-D-glycero-L-gluco-
 octonoyl)amino]acetyl]amino]- (9CI)
 MF C14 H24 N2 O9

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 23 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN L-Phenylalanine, N2-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-
 arginyl-L-histidyl-L-prolyl- (9CI)
 SQL 4
 MF C34 H49 N9 O11

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> s l1 sss full

FULL SEARCH INITIATED 10:31:37 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 670 TO ITERATE

100.0% PROCESSED 670 ITERATIONS

450 ANSWERS

SEARCH TIME: 00.00.01

L3 450 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.55

172.76

FILE 'CAPLUS' ENTERED AT 10:31:58 ON 30 JAN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jan 2007 VOL 146 ISS 6

FILE LAST UPDATED: 29 Jan 2007 (20070129/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3 and (gem(a)difluoro)

55 L3
7960 GEM
1962 GEMS
9134 GEM
(GEM OR GEMS)

14446 DIFLUORO
122 GEM(A)DIFLUORO

L4 0 L3 AND (GEM(A)DIFLUORO)

=> s l3 and difluoro

55 L3
14446 DIFLUORO

L5 0 L3 AND DIFLUORO

=> s l3 and zinc

55 L3
613510 ZINC
119 ZINCS
613533 ZINC
(ZINC OR ZINCS)

L6 1 L3 AND ZINC

=> dis l6 bib abs hitstr

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:80195 CAPLUS

DN 140:128606

TI Preparation of gem difluorinated glycoconjugates as potential antitumor,
antiviral, hypoglycemic prodrug agents

IN Quirion, Jean Charles; Pannecoucke, Xavier; D. Hooge, Francois; Marcotte,
Stephane

PA Institut National des Sciences Appliquees de Rouen INSA, Fr.

SO Fr. Demande, 27 pp.

CODEN: FRXXBL


DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2842810	A1	20040130	FR 2002-9627	20020725
	FR 2842810	B1	20060127		
	CA 2492940	A1	20040219	CA 2003-2492940	20030723
	WO 2004014928	A2	20040219	WO 2003-FR2330	20030723
	WO 2004014928	A3	20040401		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003274202	A1	20040225	AU 2003-274202	20030723
	EP 1525208	A2	20050427	EP 2003-758183	20030723
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003012917	A	20050705	BR 2003-12917	20030723
	CN 1671723	A	20050921	CN 2003-817770	20030723
	JP 2006508048	T	20060309	JP 2004-526949	20030723
	US 2006142206	A1	20060629	US 2005-522365	20050921
PRAI	FR 2002-9627	A	20020725		

WO 2003-FR2330 W 20030723
 OS CASREACT 140:128606; MARPAT 140:128606
 GI



AB Gem difluorinated glycoconjugates I, wherein R1 is an aldehyde, acid, ester, alkyl, hydroxy, amine, amide; R2 is H, free or protected function alc.; R3 is protecting group; Y is alkoxy, amine, thioalkyl, were prepared via condensation of lactone sugar with bromodifluoromethylcarboxylate in the presence of zinc or of a derivative lanthanide and used as antitumor, antiviral, hypoglycemic prodrug agents (no data). Thus, glycoconjugate II was prepared in 68 % yield via condensation of the corresponding sugar lactone with BrCF₂CO₂Et in presence of zinc.

IT 648904-18-1P


RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of gem difluorinated glycoconjugates via condensation of lactone sugar with bromodifluoromethylcarboxylate as potential antitumor, antiviral, and hypoglycemic prodrug agents)

RN 648904-18-1 CAPLUS

CN β-D-glucopyranoside, 2-deoxy-2,2-difluoro-N-[(4-methoxyphenyl)methyl]-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s 13 and reformatky

55 L3

686 REFORMATSKY

L7

0 L3 AND REFORMATSKY

=> s 13 and (process or prepara?)

55 L3

2371787 PROCESS

1612126 PROCESSES

3540094 PROCESS

(PROCESS OR PROCESSES)

1596328 PREPARA?

2778145 PREPN

207393 PREPNS

2934454 PREPN

(PREPN OR PREPNS)

3775663 PREPARA?

(PREPARA? OR PREPN)

L8 44 L3 AND (PROCESS OR PREPARA?)

=> s l8 and carbonyl

172495 CARBONYL

27506 CARBONYLS

180708 CARBONYL

(CARBONYL OR CARBONYLS)

L9 2 L8 AND CARBONYL

=> dis l9 1-2 bib abs hitstr

L9 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:716289 CAPLUS

DN 137:232918

TI Helicomimetics and stabilized LXXLL peptidomimetics

IN Spatola, Arno F.; Leduc, Anne-Marie

PA University of Louisville, USA

SO PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002072597	A2	20020919	WO 2002-US7093	20020311
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2005054770	A1	20050310	US 2004-471120	20040923
PRAI	US 2001-274846P	P	20010309		
	WO 2002-US7093	W	20020311		

OS MARPAT 137:232918

AB A helicomimetic compound for stabilizing the α -helical structure of a protein fragment, which can serve as an agonist or antagonist of protein-protein interactions, comprises a compound of structure R1-(Xn)-D-Cys-Y-Y-L-Cys-(Xn)-R2 [R1 is H, an alkyl, aryl, acetyl, formyl, or other blocking or solubilizing group, such as a polyethylene glycol (PEG) or other polyether moiety, linked to the N-terminal nitrogen through a carbon-nitrogen bond; X is one or more natural or unnatural amino acids, linked together in a chain from 0 to n in length; Y is a natural or unnatural amino acid, usually of the L-configuration, and with two such amino acids that need not be identical, separating the pairs of cysteines to form an i to i + 3 type of disulfide bridged unit; R2 is OH, NH₂, NHR, OR, or other blocking or solubilizing group, such as polyethylene glycol (PEG) or other polyether moiety, linked to the C-terminal carbonyl through an oxygen or carbon or nitrogen linkage, such as an amide group]. The invention includes helix-stabilized compds. that contain the so-called NR Box found in a large number of Nuclear Receptor Coactivator Proteins. The NR Box sequence, consisting of Leu-Xxx-Yyy-Leu-Leu within a longer peptide, is found in both coactivator proteins and also in certain nuclear

receptors. The Boc-based Merrifield solid-phase method was used to prepare linear and cyclic peptides, including H-Lys-His-Lys-Ile-Leu-His-Arg-Leu-Leu-Gln-Asp-Ser-Ser-OH (AML-I-89/2) and H-D-Lys-cyclo(D-Cys-Ile-Leu-Cys)-Arg-Leu-Leu-Gln-NH₂ (AKG-I-28). K_i values are tabulated for the peptides against estrogen receptors (ER) alpha and beta. Short linear peptides that contain the LXXLL sequence, such as Leu-Asn-Gln-Leu-Leu, do not display any inhibitory activity with respect to the desired effect of inhibiting the binding of the estrogen receptors to the helical segment of coactivator proteins. Compds. that contain a D-Cys, L-Cys pairing are especially active with respect to binding inhibition.

IT 459844-33-8P, AML-I-31


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of α -helix stabilized LXXLL peptidomimetics)

RN 459844-33-8 CAPLUS

CN L-Leucine, N-(3,7-anhydro-2-deoxy-D-manno-octonoyl)-L-leucyl-L- α -glutamyl-L-glutaminy-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:13473 CAPLUS

DN 122:56357

TI On the synthesis of C-glycosyl compounds containing double bonds without the use of protecting groups

AU Wulff, Guenter; Clarkson, Guy

CS Inst. Org. Chem. Makromol. Chem., Heinrich-Heine Univ., Duesseldorf, 40225, Germany

SO Carbohydrate Research (1994), 257(1), 81-95


CODEN: CRBRAT; ISSN: 0008-6215

DT Journal

LA English

OS CASREACT 122:56357

GI



AB A new range of C-glycosyl compds. carrying double bonds have been

synthesized as potential monomers for the prepn. of polyvinyl-saccharides. The syntheses were performed without the use of protecting groups and mostly in water as solvent. The starting material was the easily accessible 5- β -D-glycopyranosyl-1,3-dimethylbarbituric acid sodium salt I (R = Na) (obtained from D-glucose and 1,3-dimethylbarbituric acid in water). The alkylation reaction of I (R = Na) at C-5 of the barbiturate moiety was studied in detail. It works well with benzylic bromides in Me₂SO and with allylic or benzylic bromides by an ultrasound/phase transfer catalyst-promoted alkylation in water. The resulting 5,5-dialkylated barbiturates, e.g. I (R = CH₂C₆H₄-R₁, R₁ = H, CH:CH₂, CH₂CH₂Br; R = CH₂CR₂:CH₂, R₂ = H, Ph, CO₂Me), undergo an unusually facile and specific cleavage of the barbituric ring, losing the c-2 carbonyl, to yield novel mols. with a diamide moiety.

IT 160055-68-5P 160055-69-6P 160055-70-9P


160055-71-0P 160055-72-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 160055-68-5 CAPLUS

CN Propanediamide, N,N'-dimethyl-2-(phenylmethyl)-2-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160055-69-6 CAPLUS

CN Propanediamide, 2-[[4-ethenylphenyl)methyl]-N,N'-dimethyl-2-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160055-70-9 CAPLUS

CN Propanediamide, 5-[[4-(2-bromoethyl)phenyl)methyl]-N,N'-dimethyl-2-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160055-71-0 CAPLUS

CN Propanediamide, N,N'-dimethyl-2-(2-propenyl)-2-(2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160055-72-1 CAPLUS

CN Propanediamide, N,N'-dimethyl-2-(2-phenyl-2-propenyl)-2-(2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> s 18 and (carbonyl(w)addition)

172495 CARBONYL

27506 CARBONYLS

180708 CARBONYL

(CARBONYL OR CARBONYLS)

168126 ADDITION

15548 ADDITIONS

180911 ADDITION

(ADDITION OR ADDITIONS)

1567120 ADDN

73526 ADDNS

1613493 ADDN

(ADDN OR ADDNS)

1711112 ADDITION

(ADDITION OR ADDN)

579 CARBONYL(W)ADDITION

L10 0 L8 AND (CARBONYL(W)ADDITION)

=> dis l8 1-44 bib abs hitstr

L8 ANSWER 1 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:1034391 CAPLUS

DN 145:397538

TI Carboxamides as inhibitors of TGF- β and their preparation
and use in the treatment of conditions associated with excessive
TGF- β activity.

IN Axon, Jonathan; Chakravarty, Sarvajit; Hart, Barry; Mcenroe, Glenn;
Murphy, Alison; Pontius, Karen; Sheng, Daniel; Wang, Gina; Yellapregada,
Shanti

PA Scios Inc., USA

SO PCT Int. Appl., 135pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2006105222	A2	20061005	WO 2006-US11509	20060327
	WO 2006105222	A3	20061228		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	US 2006281763	A1	20061214	US 2006-390980	20060327
PRAI	US 2005-665095P	P	20050325		
OS	MARPAT 145:397538				
GI					



I



II

AB Certain appropriately substituted forms of pyrimidine, of formula I, having a pyridylamine group at C-4 of the pyrimidine and an amide group on the pyridine ring are useful in the treatment of conditions associated with excessive TGF- β activity. Compds. of formula I wherein Ar is (un)substituted phenyl; Y and Z are independently H, halo, NO₂, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted heteroalkyl, (un)substituted heteroalkenyl, etc.; R₁ is (un)substituted (hetero)alkyl, (un)substituted (hetero)acyl, (un)substituted alkoxy, (un)substituted alkylamino, (un)substituted (hetero)aryl, etc.; R₂ is H; NR₁R₂ may form (un)substituted piperidine, (un)substituted morpholine, (un)substituted piperazine, and (un)substituted pyrrolidine; W is halo NH₂ and derivs., NO₂, CN, CF₃, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, etc.; m is 0 and 1; n is 0-3; and their pharmaceutically acceptable salts are claimed. Example compound II was prepared by cyclocondensation of Et 3-methylbutanoate with Et formate and 2-fluoro-5-chlorobenzamidine; the resulting 2-(5-chloro-2-fluorophenyl)-5-isopropylpyrimidin-4-one underwent chlorination to give 4-chloro-2-(5-chloro-2-fluorophenyl)-5-isopropylpyrimidine, which underwent amination with Me 4-aminonicotinate to give Me 4-[2-(5-chloro-2-fluorophenyl)-5-isopropylpyrimidin-4-yl]nicotinate, which underwent hydrolysis to give the corresponding nicotinic acid, which underwent amination with cyclopropylamine to give compound II. All the invention compds. were evaluated for their TGF- β inhibitory activity (data given).

IT 911700-03-3P 911700-04-4P 911700-06-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of carboxamides as inhibitors of TGF- β useful in treatment of conditions associated with excessive TGF- β activity)

RN 911700-03-3 CAPLUS

CN D-gluco-Octonamide, 3,7-anhydro-N-[3-[[[4-[[2-(5-chloro-2-fluorophenyl)-5-methoxy-4-pyrimidinyl]amino]-3-pyridinyl]carbonyl]amino]propyl]-2-deoxy-, (3 ξ)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911700-04-4 CAPLUS

CN D-gluco-Octonamide, 3,7-anhydro-N-[2-[[[4-[[2-(5-chloro-2-fluorophenyl)-5-methoxy-4-pyrimidinyl]amino]-3-pyridinyl]carbonyl]amino]ethyl]-2-deoxy-, (3ξ)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911700-06-6 CAPLUS


CN D-gluco-Octonamide, 3,7-anhydro-N-[3-[[[4-[[2-(5-chloro-2-fluorophenyl)-5-methoxy-4-pyrimidinyl]amino]-3-pyridinyl]carbonyl]amino]propyl]-2-deoxy-N-(1-methylethyl)-, (3ξ)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 2 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:548991 CAPLUS
 DN 145:211327
 TI Synthesis of a galacto-configured C-ketoside-based γ -sugar-amino acid and its use in peptide coupling reactions
 AU Schweizer, Frank; Hindsgaul, Ole
 CS Department of Chemistry, University of Manitoba, Winnipeg, MB, R3T 2N2, Can.
 SO Carbohydrate Research (2006), 341(10), 1730-1736
 CODEN: CRBRAT; ISSN: 0008-6215
 PB Elsevier B.V.
 DT Journal
 LA English
 AB γ -Sugar-amino acid analogs in the form of C-ketosides can be prepared in 5-6 steps starting from D-galactono-1,5-lactone. The key step in the synthesis is the trimethylsilyl trifluoromethanesulfonate (TMSOTf) promoted C-glycosylation of 2-deoxy-3-ulopyranosonates with trimethylsilyl cyanide. Hydrogenation of the resulting β -cyano esters provides C-ketoside-based γ -sugar-amino acids that serve as building blocks for the synthesis of unnatural neoglycopeptides.
 IT 903882-01-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of a galacto-configured C-ketoside-based γ -sugar-amino acid and its use in peptide coupling reactions)
 RN 903882-01-9 CAPLUS
 CN L-Alanine, N-[3,7-anhydro-2-deoxy-3-C-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]methyl]-D-glycero-L-manno-octonoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 903882-02-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of a galacto-configured C-ketoside-based
gamma-sugar-amino acid and its use in peptide coupling reactions)

RN 903882-02-0 CAPLUS

CN L-Alanine, N-[3,7-anhydro-2-deoxy-3-C-[[[(2S)-2-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-1-oxo-3-phenylpropyl]amino]methyl]-D-glycero-L-manno-octonoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:538719 CAPLUS

DN 145:46272

TI Preparation of gem-difluorinated C-glycopeptides and their use
for the preservation of biological materials and/or in cryosurgery

IN Quirion, Jean-Charles; Castelot-Deliencourt- Godefroy, Geraldine


PA Institut National Des Sciences Appliquees De Rouen, Fr.

SO PCT Int. Appl., 87 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006059227	A1	20060608	WO 2005-IB3940	20051202
	WO 2006059227	B1	20061102		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	FR 2878851	A1	20060609	FR 2004-12782	20041202
PRAI	FR 2004-12782	A	20041202		
OS	MARPAT 145:46272				
GI					




AB The invention relates to gem-difluorinated C-glycopeptides
R4(NHCHR1CONHCHR2CONHCHR3CO)1-5R5 [R4 is H, AA1, AA1-AA2 and R5 is OH, AA1, AA1-AA2, where AA1 and AA2 are independent and represent amino acids with a non-functionalized side chain; R1, R2, R3 are independently H, Me, PhCH2, Me2CH, Me2CHCH2, EtCHMe and one of R1-R3 is 2-tetrahydropyranyl-CF2CONH(CH2)3-4 in which 2-tetrahydropyranyl is substituted by 5-Y, 4-Y' (H, OH, PhCH2O, N3, amino, mercapto, etc.), 6-R6 (H, Me, CH2OH, CH2-glycoside group, protected hydroxymethyl), 3-R7 (OH, NH2, N3, OH, NH2 or protected hydroxy or amino), 1-RB (H, OH or protected hydroxy)] for use in the preservation of biol. materials and in cryosurgery. Thus, glycopeptide I was prepared by a multistep sequence starting from Me D-galactopyranoside and studied for its effect on the preservation of HEK 293 kidney cells and blood platelets.

IT 890015-62-0P 890015-70-0P
RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of gem-difluorinated C-glycopeptides for preservation of biol. materials and/or in cryosurgery)

RN 890015-62-0 CAPLUS

CN L-Alanine, N6-(2-deoxy-2,2-difluoro- α -D-galacto-3-octulopyranosonyl)-L-lysyl-L-alanyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 890015-70-0 CAPLUS


CN L-Alanine, N6-(2-deoxy-2,2-difluoro-α-D-galacto-3-octulopyranosonoyl)-L-lysyl-L-alanyl-L-alanyl-N6-(2-deoxy-2,2-difluoro-α-D-galacto-3-octulopyranosonoyl)-L-lysyl-L-alanyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl




IT 890015-56-2P 890015-57-3P 890015-58-4P
 890015-60-8P 890015-61-9P 890015-66-4P
 890015-68-6P 890015-69-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. of gem-difluorinated C-glycopeptides for preservation
 of biol. materials and/or in cryosurgery)

RN 890015-56-2 CAPLUS

CN L-Lysine, N6-[2-deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-(phenylmethyl)-
 α -D-galacto-3-octulopyranosonoyl]-N2-[(1,1-dimethylethoxy)carbonyl]-
 , methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 890015-57-3 CAPLUS

CN L-Lysine, N6-[2-deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-(phenylmethyl)-
 α -D-galacto-3-octulopyranosonoyl]-N2-[(1,1-dimethylethoxy)carbonyl]-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 890015-58-4 CAPLUS

CN L-Alanine, N6-[2-deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-(phenylmethyl)-
α-D-galacto-3-octulopyranosonoyl]-N-[(1,1-dimethylethoxy)carbonyl]-L-
lysyl-L-alanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 890015-60-8 CAPLUS


CN L-Alanine, N6-[2-deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-(phenylmethyl)-
α-D-galacto-3-octulopyranosonoyl]-L-lysyl-L-alanyl-, methyl ester,
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 890015-59-5

CMF C49 H60 F2 N4 O11


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 890015-61-9 CAPLUS

CN L-Alanine, N6-[2-deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-(phenylmethyl)-
α-D-galacto-3-octulopyranosonoyl]-L-lysyl-L-alanyl-,
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.





● HCl

RN 890015-66-4 CAPLUS

CN L-Alanine, N6-[2-deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-(phenylmethyl)-
α-D-galacto-3-octulopyranosonoyl]-N2-[(1,1-dimethylethoxy)carbonyl]-
L-lysyl-L-alanyl-L-alanyl-N6-[2-deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-
(phenylmethyl)-α-D-galacto-3-octulopyranosonoyl]-L-lysyl-L-alanyl-,
methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 890015-68-6 CAPLUS



CN L-Alanine, N6-[2-deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-(phenylmethyl)- α -D-galacto-3-octulopyranosonyl]-L-lysyl-L-alanyl-L-alanyl-N6-[2-deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-(phenylmethyl)- α -D-galacto-3-octulopyranosonyl]-L-lysyl-L-alanyl-, methyl ester, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 890015-67-5

CMF C97 H116 F4 N8 O21


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 890015-69-7 CAPLUS

CN L-Alanine, N6-[2-deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-(phenylmethyl)-
 α -D-galacto-3-octulopyranosonoyl]-L-lysyl-L-alanyl-L-alanyl-N6-[2-
 deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-(phenylmethyl)- α -D-galacto-3-
 octulopyranosonoyl]-L-lysyl-L-alanyl-, monohydrochloride (9CI) (CA INDEX
 NAME).

Absolute stereochemistry.



● HCl



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1314244 CAPLUS
DN 144:51830
TI Synthesis of metabolically stable analgesics, pain medications and other agents
IN Cashman, John R.; Macdougall, James M.
PA Human Biomolecular Research Institute, USA
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005117589	A1	20051215	WO 2005-US19000	20050531
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,				

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
 NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
 SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
 ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

PRAI US 2004-575451P P 20040528
 OS MARPAT 144:51830
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Disclosed are analgesic-related compns. ABC [A = analgesic, opiate or derivative; B = linking group (e.g. S, NHC(:O)(CH₂)_n; n = 0 - 5); C = (un)substituted aryl, heteroaryl, saccharide {e.g., Z; R₈ = H, (C1-5-alkyl)C(:O), (C7-10-aralkyl)C(:O), C7-10-aralkyl, C1-5-alkyl, C6-12-aryl, (C6-12-aryl)C(:O); R₉ = CH₂OH, CH₂O(C1-5-alkyl), CH₂O₂C(C1-5-alkyl), CH₂O(C6-12-aryl), CO₂H, CO₂(C1-5-alkyl), CO₂(C6-12-aryl), CO₂(C7-10-aralkyl)}] and methods of using the compns. for modulation of analgesic receptor activity. Analgesics I [R₁ = H, (C1-5-alkyl)C(:O), (C7-10-aralkyl)C(:O), C7-10-aralkyl, C1-5-alkyl, C6-12-aryl, (C6-12-aryl)C(:O), silyl; R₂ = C1-5-alkyl, C3-6-cycloalkyl, (C3-6-cycloalkyl)alkyl, (C5-7-cycloalkenyl)alkyl, C6-12-aryl, C7-12-aralkyl, C6-12-heteroaryl, C7-12-heteroaralkyl, C2-5-alkenyl, C2-5-alkynyl (each optionally substituted with halogen, C1-5-alkoxy, NO₂, CO₂R); R₃ = H, OH, R₄ = H; R₅ = H; R₆ = YR₇; R₅R₆ = heteroaryl; R₇ = (un)substituted aryl, heteroaryl, saccharide; R = H, C1-5-alkyl; Y = S, NHC(:O)(CH₂)_n] are selected from alkaloids naltrexone, phenylpiperidine, piperidinol, prodine, piperidylpropionanilide, isoprodine, prodilidine, benzomorphan, morphan, azabicyclane, morphinan, [(diphenylamnio)ethyl]propionate, methadone, isomethadone, propoxyphene, dextromethorphan, benzazocin-8-ol, norbinaltrophine, naltrindole, guanidinylnaltrindole. Thus, morphine thioglycoside II was prepared from morphine 6-O-tosylate via thioglycosylation with Me [2,3,4-tri-O-acetyl-β-D-glucopyranosyluronate]-1-thiol in DMF containing NaH followed by saponification. The compns. and methods are useful for reducing pain, as well

as
 for therapeutic intervention of addictions or other diseases or disorders amenable to treatment or prophylaxis by modulation of analgesic receptor signaling. The analgesic activity of II was determined [K_i = 8.73 nM vs. μ opioid receptor; K_i = 31.4 nM vs. δ opioid receptor; K_i = 288 nM vs. κ opioid receptor; EC₅₀ = 33.7 nM for stimulation of [35S]GTPγS binding at μ opioid receptor; EC₅₀ = 50.13 nM for stimulation of [35S]GTPγS binding at δ opioid receptor].


IT 851217-50-0P 871119-49-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and desilylation of; synthesis of metabolically stable analgesics, pain medications and related agents)

RN 851217-50-0 CAPLUS

CN D-glycero-D-gulo-Octonamide, 3,7-anhydro-2-deoxy-N-[(5α,6β)-7,8-didehydro-4,5-epoxy-17-methyl-3-[[tris(1-methylethyl)silyl]oxy]morphinan-6-yl]-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 871119-49-2 CAPLUS

CN L-glycero-L-gulo-Octonic acid, 2,6-anhydro-7,8-dideoxy-8-
[[(5 α ,6 β)-7,8-didehydro-3-[[(1,1-dimethylethyl)dimethylsilyl]ox
y]-4,5-epoxy-17-methylmorphinan-6-yl]amino]-8-oxo-, methyl ester,
3,4,5-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 851217-51-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. and hydrogenation/debenzylation of; synthesis of
metabolically stable analgesics, pain medications and related agents)

RN 851217-51-1 CAPLUS


CN D-glycero-D-gulo-Octonamide, 3,7-anhydro-2-deoxy-N-[(5 α ,6 β)-7,8-
didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]-4,5,6,8-tetrakis-O-
(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 871119-51-6P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. and saponification of; synthesis of metabolically stable analgesics, pain medications and related agents)
 RN 871119-51-6 CAPLUS
 CN L-glycero-L-gulo-Octonic acid, 2,6-anhydro-7,8-dideoxy-8-[[[(5 α ,6 β)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]amino]-8-oxo-, methyl ester, 3,4,5-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 871119-68-5P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn., hydrogenolytic debenzoylation and receptor binding of; synthesis of metabolically stable analgesics, pain medications and related agents)
 RN 871119-68-5 CAPLUS
 CN D-glycero-D-gulo-Octonamide, 3,7-anhydro-N-[(5 α)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 871119-58-3P
 RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn., saponification and opioid antagonistic of; synthesis of metabolically stable analgesics, pain medications and related agents)
 RN 871119-58-3 CAPLUS
 CN L-glycero-L-gulo-Octonic acid, 2,6-anhydro-7,8-dideoxy-8-[[[(5 α ,6 β)-7,8-didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-

6-yl]amino]-8-oxo-, methyl ester, 3,4,5-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 851217-54-4P 871119-52-7P 871119-61-8P


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis of metabolically stable analgesics, pain medications and related agents)

RN 851217-54-4 CAPLUS

CN D-glycero-D-gulo-Octonamide, 3,7-anhydro-2-deoxy-N-[(5 α ,6 β)-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 871119-52-7 CAPLUS


CN D-glycero-L-gulo-Octonic acid, 2,6-anhydro-7,8-dideoxy-8-[[[(5 α ,6 β)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]amino]-8-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 871119-61-8 CAPLUS
 CN D-glycero-L-gulo-Octonic acid, 2,6-anhydro-7,8-dideoxy-8-
 [[(5 α ,6 β)-7,8-didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-
 6-yl]amino]-8-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 851217-52-2P 871119-69-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (synthesis of metabolically stable analgesics, pain medications and
 related agents)


RN 851217-52-2 CAPLUS
 CN D-glycero-D-gulo-Octonamide, 3,7-anhydro-2-deoxy-N-[(5 α ,6 β)-4,5-
 epoxy-3-hydroxy-17-methylmorphinan-6-yl]-4,5,6,8-tetrakis-O-(phenylmethyl)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 871119-69-6 CAPLUS
 CN D-glycero-D-gulo-Octonamide; 3,7-anhydro-N-[(5 α)-17-
 (cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-2-deoxy- (9CI)
 (CA INDEX NAME)



Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:386328 CAPLUS
 DN 143:406117
 TI Antifreeze glycoprotein analogs: Synthesis, in vitro testing, and applications
 AU Bouvet, Vincent; Ben, Robert N.
 CS Department of Chemistry, D'Iorio Hall, University of Ottawa, Ottawa, ON, K1N 6N5, Can.
 SO ACS Symposium Series (2005), 896(Glycomimetics), 151-166
 CODEN: ACSMC8; ISSN: 0097-6156
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 143:406117
 AB A series of first generation C-linked antifreeze glycoprotein (AFGP) analogs have been successfully prepared using conventional solid phase chemical. These glycoconjugates range in mol. weight between 1.5 to 4.1 Kda and can be prepared using traditional linear solid phase protocol. Unlike the native system, the C-linked analogs possess enhanced chemical and biol. stability and consequently are well-suited for many potential medical, industrial and com. applications. Despite dramatic structural modifications (relative to the native system), several of these first generation analogs display significant antifreeze protein-specific activity.
 IT 255851-86-6P 592532-44-0P
 RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. and in vitro testing of glycopeptides as analogs of antifreeze glycoproteins)
 RN 255851-86-6 CAPLUS
 CN Glycine, N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.





RN 592532-44-0 CAPLUS

CN Glycine, N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







PAGE 2-A



PAGE 2-B



PAGE 2-C




PAGE 2-D



IT 255851-83-3P 255851-84-4P 592532-40-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. and in vitro testing of glycopeptides as analogs of
antifreeze glycoproteins)
RN 255851-83-3 CAPLUS
CN Glycine, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-N6-(4,5,6,8-tetra-O-acetyl-
3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycyl-,
phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 255851-84-4 CAPLUS

CN Glycine, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 592532-40-6 CAPLUS

CN Glycine, N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 6 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:137046 CAPLUS
 DN 142:374105
 TI Access to unnatural glycosyl amino acid building blocks via a one-pot Ritter reaction
 AU Penner, Marlin; Taylor, David; Desautels, Danielle; Marat, Kirk; Schweizer, Frank
 CS Department of Chemistry, University of Manitoba, Winnipeg, MB, R3T 2N2, Can.
 SO Synlett (2005), (2), 212-216
 CODEN: SYNLES; ISSN: 0936-5214
 PB Georg Thieme Verlag
 DT Journal
 LA English
 OS CASREACT 142:374105
 AB α -D-Galacto-2-deoxy-oct-3-ulopyranosonic acids, α -D-gluco-2-deoxy-oct-3-ulopyranosonic acids and α -L-galacto-2,8-dideoxy-oct-3-ulopyranosonic acids can be converted into unnatural glycosyl amino acids via a one-pot intramol. Ritter reaction. Initially, a ketopyranoside-based acid condenses under Lewis acid-promoted conditions with a nitrile (benzonitrile or acetonitrile) and a partially protected diamino ester (Boc-DAB-Ot-Bu, Boc-Orn-Ot-Bu) to form unnatural glycosyl amino esters. The resulting glycosyl amino esters are useful building blocks for solid-phase glycopeptide synthesis. For example, the glycosyl amino acid derived by condensation of α -D-galacto-2-deoxy-oct-3-ulopyranosonic acid with benzonitrile and DAB was used to replace serine in the potent opioid peptide sequence H₂N-Tyr-D-Thr-Gly-Phe-Leu-Ser-CONH₂.
 IT 849472-56-6P 849472-65-7P 849472-72-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of glycosyl amino acids via one-pot Ritter reaction of ketopyranoside-based acid with benzonitrile or acetonitrile for solid phase glycopeptide synthesis)
 RN 849472-56-6 CAPLUS
 CN Butanoic acid, 4-[[[3-(benzoylamino)-2,3-dideoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- α -D-galacto-3-octulopyranosonyl]amino]-2-[[[1,1-dimethylethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849472-65-7 CAPLUS
 CN Butanoic acid, 2-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-[[[4,5,6,8-tetra-O-acetyl-3-(benzoylamino)-2,3-dideoxy- α -D-galacto-3-octulopyranosonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849472-72-6 CAPLUS

CN Butanoic acid, 2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-[[4,5,6,8-tetra-O-acetyl-3-(benzoylamino)-2,3-dideoxy- α -D-galacto-3-octulopyranosonoyl]amino]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 849472-57-7P 849472-58-8P 849472-59-9P
849472-60-2P 849472-61-3P 849472-64-6P
849472-66-8P 849472-68-0P 849472-69-1P
849472-70-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of glycosyl amino acids via one-pot Ritter reaction
of ketopyranoside-based acid with benzonitrile or acetonitrile for
solid phase glycopeptide synthesis)

RN 849472-57-7 CAPLUS

CN L-Ornithine, N5-[3-(benzoylamino)-2,3-dideoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- α -D-galacto-3-octulopyranosonoyl]-N2-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849472-58-8 CAPLUS

CN L-Ornithine, N5-[3-(acetamido)-2,3-dideoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-galacto-3-octulopyranosonoyl]-N2-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849472-59-9 CAPLUS

CN Butanoic acid, 4-[[3-(benzoylamino)-2,3-dideoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-gluco-3-octulopyranosonoyl]amino]-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849472-60-2 CAPLUS

CN L-Ornithine, N5-[3-(benzoylamino)-2,3-dideoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-gluco-3-octulopyranosonoyl]-N2-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849472-61-3 CAPLUS

CN L-Ornithine, N5-[3-(acetylamino)-2,3-dideoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-glucopyranosonoyl]-N2-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849472-64-6 CAPLUS

CN L-Alanine, N-[3-(benzoylamino)-2,3-dideoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-galactopyranosonoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 849472-66-8 CAPLUS


CN Butanamide, L-tyrosyl-D-threonylglycyl-L-phenylalanyl-L-leucyl-2-amino-4-[[3-(benzoylamino)-2,3-dideoxy-α-D-galactopyranosonoyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 849472-68-0 CAPLUS

CN Carbamic acid, [3-[[2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-N-propyl- α -D-galacto-3-octulopyranosonamidosyl]amino]-3-oxopropyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849472-69-1 CAPLUS


CN β -Alanine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]- β -alanyl-3-amino-2,3-dideoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- α -D-galacto-3-octulopyranosonyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849472-70-4 CAPLUS
 CN α -D-gluco-3-Octulopyranosonamide, 3-(benzoylamino)-2,3-dideoxy-N-(phenylmethyl)-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:837270 CAPLUS
 DN 141:337274
 TI Cosmetic use of new desquamative agents
 IN Dalko, Maria; Cavezza, Alexandre; Bernard, Dominique
 PA L'oreal, Fr.
 SO Eur. Pat. Appl., 18 pp.
 CODEN: EPXXDW
 DT Patent
 LA French
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1466590	A1	20041013	EP 2004-290756	20040322
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	FR 2853540	A1	20041015	FR 2003-4349	20030408
	FR 2853540	B1	20060707		
	US 2005002889	A1	20050106	US 2004-813056	20040331

JP 2004307508	A	20041104	JP 2004-113511	20040407
JP 3808082	B2	20060809		
PRAI FR 2003-4349	A	20030408		
US 2003-471725P	P	20030520		
OS MARPAT 141:337274				
GI				




AB Cosmetic compns. containing I are used for topical used on hair or skin to prevent aging and improve the color of the skin and dry skin. Thus, 2-benzyl-N,N'-dimethyl-2-(3,4,5-trihydroxy-6-methyltetrahydropyran-2-yl)-malonamide was prepared and its efficacy in separating corneocytes from stratum corneum was shown. Formulation of an anti-acne gel is containing 3.0% active compound was disclosed.

IT 769140-43-4P
 RL: COS (Cosmetic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (cosmetic use of new desquamative agents)

RN 769140-43-4 CAPLUS

CN Propanediamide, 2-β-D-glucopyranosyl-N,N'-dimethyl-2-(phenylmethyl)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 8 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:536729 CAPLUS

DN 141:225760

TI Preparation of an advanced intermediate for the synthesis of stable analogs of guanofosfocin

AU George, Tesmol G.; Szolcsanyi, Peter; Koenig, Stefan G.; Paterson, Duncan E.; Isshiki, Yoshiaki; Vasella, Andrea

CS Laboratorium fuer Organische Chemie, ETH-Hoenggerberg, Zurich, CH-8093, Switz.

SO Helvetica Chimica Acta (2004), 87(5), 1287-1298
 CODEN: HCACAV; ISSN: 0018-019X


PB Verlag Helvetica Chimica Acta

DT Journal

LA English

OS CASREACT 141:225760

GI



I

AB The synthesis of a C-mannosyl-guanosine, I, an advanced intermediate for the prepn. of stable analogs of guanosine, is described. This convergent approach features an improved Traube-type synthesis of a 8-substituted guanine, followed by ribosylation. NMR Studies show that the C-mannopyranosyl moiety of I adopts a distorted 1C4 conformation while the nucleoside is predominantly syn-oriented.

IT 745822-38-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of a C-mannosyl-guanosine analog via Traube-type synthesis of the 8-substituted guanine followed by ribosylation)

RN 745822-38-2 CAPLUS

CN D-glycero-D-talo-Octonamide, N-[2-amino-5-nitroso-6-(phenylmethoxy)-4-pyrimidinyl]-3,7-anhydro-2-deoxy-4,6,8-tris-O-(phenylmethyl)-, 5-acetate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:252533 CAPLUS

DN 140:287715

TI Preparation of modified peptide nucleic acid (PNA) prodrugs

IN Rasmussen, Palle; Frandsen, Niels Montano; Nyborg, Marlene; Rasmussen, Frank Winther; Hamzavi, Ramin; Nielsen, Peter Eigild; Kjaerulff, Soren

PA Santaris Pharma A/s, Den.

SO PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004024757	A2	20040325	WO 2003-DK588	20030911
	WO 2004024757	A3	20040429		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2498772	A1	20040325	CA 2003-2498772	20030911
	AU 2003260289	A1	20040430	AU 2003-260289	20030911
	EP 1543019	A2	20050622	EP 2003-794821	20030911
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	DK 2002-1334	A	20020911		
	DK 2002-1786	A	20021119		
	DK 2002-1956	A	20021220		
	DK 2003-600	A	20030416		
	WO 2003-DK588	W	20030911		
OS	MARPAT 140:287715				


AB The invention relates to peptide nucleic acid (PNA) drugs, which are optionally modified in order to obtain novel PNA mols. with cell-specific delivery. PNA monomers RNHCHR1CHR2N(COCH2-B)CHR3CO2H [B is a naturally-occurring nucleobase (preferably A, T, G, or C) or a non-naturally-occurring nucleobase; R is H or a protecting group; R1, R2, R3 are H, an amino acid side chain, substituted alkyl, etc.] are claimed. The examples describe of PNAs, e.g., [GalNAc(OH)3]2-Lys-Gly-CATCACTGGCAGACCCTG-NH2, and PNA conjugates. A table shows the effect of GalNAc ligands on PNA delivery to the liver.

IT 675600-89-2P 675600-90-5P 675600-92-7P
675600-93-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of modified peptide nucleic acid (PNA) prodrugs)

RN 675600-89-2 CAPLUS

CN L-Lysine, N2-[2-[[[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl][(1,1-dimethylethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)




Absolute stereochemistry.

RN 675600-90-5 CAPLUS

CN L-Lysine, N2-[2-[[[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl][(1,1-dimethylethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 675600-92-7 CAPLUS

CN L-Lysine, N2-[2-[[[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl][(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 675600-93-8 CAPLUS


CN L-Lysine, N2-[2-[[[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl][(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 675601-12-4P 675601-13-5P 675601-14-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of modified peptide nucleic acid (PNA) prodrugs)
 RN 675601-12-4 CAPLUS
 CN L-Lysine, N2-[2-[[[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl][(1,1-dimethylethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 675601-13-5 CAPLUS
 CN L-Lysine, N2-[2-[[[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl][(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 675601-14-6 CAPLUS

CN L-Lysine, N2-[2-[[[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl][(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 10 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:80195 CAPLUS

DN 140:128606

TI Preparation of gem difluorinated glycoconjugates as potential antitumor, antiviral, hypoglycemic prodrug agents

IN Quirion, Jean Charles; Pannecoucke, Xavier; D. Hooge, Francois; Marcotte, Stephane

PA Institut National des Sciences Appliquees de Rouen INSA, Fr.

SO Fr. Demande, 27 pp.



CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2842810	A1	20040130	FR 2002-9627	20020725
	FR 2842810	B1	20060127		
	CA 2492940	A1	20040219	CA 2003-2492940	20030723
	WO 2004014928	A2	20040219	WO 2003-FR2330	20030723
	WO 2004014928	A3	20040401		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003274202	A1	20040225	AU 2003-274202	20030723
	EP 1525208	A2	20050427	EP 2003-758183	20030723
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003012917	A	20050705	BR 2003-12917	20030723
	CN 1671723	A	20050921	CN 2003-817770	20030723
	JP 2006508048	T	20060309	JP 2004-526949	20030723
	US 2006142206	A1	20060629	US 2005-522365	20050921
PRAI	FR 2002-9627	A	20020725		
	WO 2003-FR2330	W	20030723		
OS	CASREACT 140:128606; MARPAT 140:128606				
GI					



AB Gem difluorinated glycoconjugates I, wherein R₁ is an aldehyde, acid, ester, alkyl, hydroxy, amine, amide; R₂ is H, free or protected function alc.; R₃ is protecting group; Y is alkoxy, amine, thioalkyl, were prepared via condensation of lactone sugar with bromodifluoromethylcarboxylate in the presence of zinc or of a derivative lanthanide and used as antitumor, antiviral, hypoglycemic prodrug agents (no data). Thus, glycoconjugate II was prepared in 68 % yield via condensation of the corresponding sugar lactone with BrCF₂CO₂Et in presence of zinc.

IT 648904-18-1P


RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of gem difluorinated glycoconjugates via condensation of lactone sugar with bromodifluoromethylcarboxylate as potential antitumor, antiviral, and hypoglycemic prodrug agents)

RN 648904-18-1 CAPLUS

CN β-D-gluco-3-Octulopyranosonamide, 2-deoxy-2,2-difluoro-N-[(4-methoxyphenyl)methyl]-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:901818 CAPLUS
DN 140:199515
TI Carbohydrate-protein interactions at interfaces: comparison of the binding of Ricinus communis lectin to two series of synthetic glycolipids using surface plasmon resonance studies
AU Critchley, P.; Clarkson, G. J.
CS Department of Chemistry, University of Warwick, Coventry, CV4 7AL, UK
SO Organic & Biomolecular Chemistry (2003), 1(23), 4148-4159
CODEN: OBCRAK; ISSN: 1477-0520
PB Royal Society of Chemistry
DT Journal
LA English
OS CASREACT 140:199515
AB Two C-lactosyl lipids and the related C-galactosyl lipids have been synthesized and their binding to RCA120 plant lectin was compared with a second series of thiolactosylethoxyalkanes. The interactions were measured quant. in real time by surface plasmon resonance (BIAcore) at a range of concns. and temps. from 5 to 30 °C. The C-galactosyl lipid (1,3-dimethyl-5-[β-d-galactopyranosyl]-5-(4-octadecyloxybenzyl)pyrimidine-2,4,6-trione) bound much more weakly with a $K_A = 8.86 \times 10^5$ than the corresponding C-lactosyl lipid (1,3-dimethyl-5-[β-d-galactopyranosyl-(1 4)-β-d-glucopyranosyl]-5-(4-octadecyloxybenzyl)pyrimidine-2,4,6-trione) ($K_A = 2.31 \times 10^7$). The influence of the linker region of the two different series of lactosyl lipids was clearly demonstrated by the differences in the binding to RCA120 lectin. The changes in kinetic values and in the enthalpic and entropic contribution to the free energy of binding reflected the importance of the linker and the hydrocarbon anchor holding the synthetic glycolipids in the neomembrane.
IT 660850-45-3P 660850-46-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(comparison of the binding of Ricinus communis lectin to synthetic glycolipids using surface plasmon resonance studies)
RN 660850-45-3 CAPLUS
CN Propanediamide, N,N'-dimethyl-2-[[4-(octadecyloxy)phenyl]methyl]-2-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 660850-46-4 CAPLUS

CN Propanediamide, N,N'-dimethyl-2-[[4-(octadecyloxy)phenyl]methyl]-2-[2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-beta-D-galactopyranosyl)-beta-D-glucopyranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 660850-39-5P 660850-40-8P

RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent) (prepn., acetylation and binding kinetics of; comparison of the binding of Ricinus communis lectin to synthetic glycolipids using surface plasmon resonance studies)

RN 660850-39-5 CAPLUS

CN Propanediamide, 2-beta-D-galactopyranosyl-N,N'-dimethyl-2-[[4-(octadecyloxy)phenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 660850-40-8 CAPLUS

CN Propanediamide, 2-(4-O-β-D-galactopyranosyl-β-D-glucopyranosyl)-
N,N'-dimethyl-2-[[4-(octadecyloxy)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:737362 CAPLUS

DN 139:261505

TI Preparation of phosphotetrahydropyran monosaccharide phosphates
as antiinflammatory agents and in treating diseases dependent on
T-lymphocyte migration

IN Cowden, William Butler; Eschler, Bart Michael; March, Darren Ray; Francis,
Douglas John; Gerba, Sendaba; Bartell, Gavin James; Charlton, Brett

PA Pharmaxis Pty Ltd., Australia

SO U.S. Pat. Appl. Publ., 32 pp., Cont.-in-part of Appl. No. PCT/AU01/00831.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003176363	A1	20030918	US 2003-338679	20030109
	US 6878690	B2	20050412		
	WO 2002004472	A1	20020117	WO 2001-AU831	20010711


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI AU 2000-8723 A 20000711

WO 2001-AU831 A2 20010711

OS MARPAT 139:261505

GI



AB The present invention provides phosphotetrahydropyran compds. I, wherein R is axial or equatorial and is selected from the group consisting of: alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cyano, hydroxy-tetrahydro-pyranyloxyalkyl, (CH₂)_nCH₂OR", (CH₂)_nCONHR", (CH₂)_nCH₂NHR" and (CH₂)_nCOX, wherein n represents an integer from 0 to 20 inclusive; R" is selected from the group consisting of H, alkyl, aryl and acyl; and X is selected from the group consisting of Y, OY' and NY"Y'" wherein Y is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl and carbohydrate; Y' is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl and carbohydrate; and Y" and Y'" are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl and acyl; wherein each of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl and acyl may be optionally substituted; provided that R is not Me, and the use thereof in treating diseases or conditions that are dependent on T-lymphocyte migration, as well as compns. containing said compds. Wherein the disease or condition is rheumatoid arthritis, multiple sclerosis, acute disseminated encephalomyelitis, psoriasis, Crohn's disease, T cell-mediated dermatitis, stromal keratitis, uveitis, thyroiditis, sialitis or type I diabetes. Thus, 3-phenyl-2-[2-(3,4,5-trihydroxy-6-phosphonooxymethyl-tetrahydro-pyran-2-yl)-acetyl amino]-propionic acid monosodium salt was prepared and tested at a dose of 62 mg/kg/day s.c., on passively transferred autoimmune encephalomyelitis (EAE) in Lewis rats.

IT 388593-58-6P 388593-75-7P 388593-81-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phosphotetrahydropyran monosaccharide phosphates as antiinflammatory agents and in treating diseases dependent on tlymphocyte migration)

RN 388593-58-6 CAPLUS

CN L-Phenylalanine, N-[(3ξ)-3,7-anhydro-2-deoxy-8-O-phosphono-D-manno-octonoyl]-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 388593-75-7 CAPLUS

CN L-Glutamic acid, N-[(3ξ)-3,7-anhydro-2-deoxy-8-O-phosphono-D-manno-octonoyl]-, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 Na

RN 388593-81-5 CAPLUS

CN D-manno-Octonamide, 3,7-anhydro-2-deoxy-N-(2-phenylethyl)-, 8-(dihydrogen phosphate), monosodium salt, (3ξ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

IT 388593-61-1P 388593-62-2P 388593-64-4P

388593-78-0P 388593-79-1P 388593-80-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of phosphotetrahydropyran monosaccharide phosphates
as antiinflammatory agents and in treating diseases dependent on
tlymphocyte migration)

RN 388593-61-1 CAPLUS

CN L-Phenylalanine, N-[(3ξ)-4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-manno-octonoyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388593-62-2 CAPLUS

CN L-Phenylalanine, N-[(3ξ)-3,7-anhydro-2-deoxy-D-manno-octonoyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388593-64-4 CAPLUS

CN L-Phenylalanine, N-[(3ξ)-4,5,6-tri-O-acetyl-3,7-anhydro-2-deoxy-D-manno-octonoyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388593-78-0 CAPLUS


CN L-Glutamic acid, N-[(3ξ)-3,7-anhydro-2-deoxy-4,5,6-tris-O-(phenylmethyl)-D-manno-octonoyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388593-79-1 CAPLUS
 CN L-Glutamic acid, N-[(3ξ)-3,7-anhydro-2-deoxy-4,5,6-tris-O-(phenylmethyl)-8-O-phosphono-D-manno-octonoyl]-, 1,5-[bis(phenylmethyl)] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388593-80-4 CAPLUS
 CN L-Glutamic acid, N-[(3ξ)-3,7-anhydro-2-deoxy-8-O-phosphono-D-manno-octonoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:679388 CAPLUS
 DN 139:381726
 TI Modulation of the Pharmacokinetic Properties of PNA: Preparation of Galactosyl, Mannosyl, Fucosyl, N-Acetylgalactosaminy, and N-Acetylglucosaminy Derivatives of Aminoethylglycine Peptide Nucleic Acid Monomers and Their Incorporation into PNA Oligomers
 AU Hamzavi, Ramin; Dolle, Frederic; Tavitian, Bertrand; Dahl, Otto; Nielsen, Peter E.
 CS Center for Biomolecular Recognition, Department of Medical Biochemistry

and Genetics, University of Copenhagen, Copenhagen, DK-2200, Den.
 SO Bioconjugate Chemistry (2003), 14(5), 941-954
 CODEN: BCCHES; ISSN: 1043-1802
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 139:381726
 GI



AB A series of N-(2-aminoethyl)- α -amino acid thymine peptide nucleic acid (PNA) monomers bearing glycosylated side chains in the α -amino acid position (e.g, I) have been synthesized. These include PNA monomers where glycine has been replaced by serine and threonine (O-glycosylated), derivs. of lysine and nor-alanine (C-glycosylated), and amide derivs. of aspartic acid (N-glycosylated). The Boc and Fmoc derivs. of these monomers were used for incorporation in PNA oligomers. Twelve PNA decamers containing the glycosylated units in one, two, or three positions were prepared, and the thermal stability (T_m) of their complexes with a complementary RNA was determined. Incorporation of the glycosyl monomers reduced the duplex stability by 0-6° C per substitution. A cysteine was attached to the amino terminus of eight of the PNA decamers (Cys-CTCATCTCT-NH₂) for easy conjugation to a [18F]radiolabeled N-(4-fluorobenzyl)-2-bromoacetamide. The in vivo biodistribution of these PNA oligomers was determined in rat 2 h after i.v. administration. Most of the radioactivity was recovered in the kidneys and in the urine. However, N-acetylgalactosamine (and to a lesser extent galactose and mannose)-modified PNAs were effectively targeting the liver (40-fold over unmodified PNA). Thus, the pharmacodistribution in rats of PNA oligomers can be profoundly changed by glycosylation. These results could be of great significance for PNA drug development, as they should allow modulation and fine-tuning of the pharmacokinetic profile of a drug lead.

IT 612491-01-7P 612491-03-9P 612491-04-0P
 612491-06-2P 612491-22-2P 612491-23-3P
 612491-25-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of glycosylated monomers for PNA synthesis and their effect on PNA/RNA hybridization or PNA biodistribution)

RN 612491-01-7 CAPLUS

CN L-Lysine, N2-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N2-[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-, 2-propenyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 612491-03-9 CAPLUS

CN L-Lysine, N2-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N2-[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-, 2-propenyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 612491-04-0 CAPLUS

CN L-Lysine, N2-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N2-[2-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612491-06-2 CAPLUS

CN L-Lysine, N2-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N2-[2-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612491-22-2 CAPLUS

CN L-Lysine, N2-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N2-[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612491-23-3 CAPLUS

CN L-Lysine, N2-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N2-[2-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612491-25-5 CAPLUS


CN L-Lysine, N2-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N2-[2-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 14 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:451473 CAPLUS
DN 140:128552
TI Synthesis and applications of alkylated C-sugars as peptide bioconjugates
AU Brunel, Florence M.; Leduc, Anne-Marie; Mashuta, Mark S.; Taylor, K.
Grant; Spatola, Arno F.
CS Department of Chemistry, University of Louisville, Louisville, KY, USA
SO Letters in Peptide Science (2003), Volume Date 2002, 9(2-3), 111-117
CODEN: LPSCEM; ISSN: 0929-5666
PB Kluwer Academic Publishers
DT Journal
LA English
OS CASREACT 140:128552
GI



AB Permethylated C-sugars affect the stability and solubility of their carbohydrate precursors and may represent an important group of bioconjugates. When properly functionalized, these units can be appended to the N- and C-termini or to the side chains of peptides or other therapeutic candidates. An amine-functionalized alkylated mannose derivative I (R = CH₂NH₂) was synthesized and its configuration was confirmed by determining the X-ray crystal structure of its nitrile precursor I (R = CN).

An acid functionalized counterpart II, when attached to the N-terminus of a NR box peptide analog, improved binding to estrogen receptor β (ERβ) but not to ERα.


IT 457617-62-8P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
BIOL (Biological study); PREP (Preparation)
(synthesis and estrogen receptor binding activity of alkylated C-sugars as peptide bioconjugates)

RN 457617-62-8 CAPLUS
CN L-Glutamamide, N2-(3,7-anhydro-2-deoxy-4,5,6,8-tetra-O-methyl-D-glycero-D-talo-octonoyl)-L-lysyl-D-cysteinyl-L-isoleucyl-L-leucyl-L-cysteinyl-L-


arginyl-L-leucyl-L-leucyl-, cyclic (2→5)-disulfide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A




RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 15 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:427283 CAPLUS

DN 139:230977


TI A serendipitous discovery of antifreeze protein-specific activity in
C-linked antifreeze glycoprotein analogs



RN 592532-40-6 CAPLUS

CN Glycine, N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycyl-
(9CI) (CA INDEX NAME)



Absolute stereochemistry.





RN 592532-44-0 CAPLUS

CN Glycine, N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-
lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-
lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-
lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-
lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-
lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-
lysylglycylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







PAGE 2-A



PAGE 2-B



PAGE 2-C




PAGE 2-D




IT 255851-84-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. and evaluation of C-linked antifreeze glycoprotein
oligopeptide analogs using recrystn. inhibition)
RN 255851-84-4 CAPLUS
CN Glycine, N2-[(9H-fluoren-9-ylmethoxy) carbonyl]-N6-(4,5,6,8-tetra-O-acetyl-
3,7-anhydro-2-deoxy-D-glycero-L-gluc-octonoyl)-L-lysylglycyl- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8. ANSWER 16 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:91084 CAPLUS
DN 139:261462
TI Synthesis of permethylated α -D-mannosyl-acetic acid, a new type of
bio-conjugate
AU Brunel, Florence M.; Taylor, K. Grant; Spatola, Arno F.
CS Department of Chemistry and the Institute for Molecular Diversity and Drug
Design, University of Louisville, Louisville, KY, 40292, USA
SO Tetrahedron Letters (2003), 44(6), 1287-1289
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 139:261462
GI



AB A concise stereoselective 3-step conversion of Me α -D-mannopyranoside to α -D-2,3,4,6-tetra-O-methyl-mannosyl-acetic acid I is described. After methylation of the alc. functions, an allylation is performed. Mannopyranoside The resulting alkene undergoes oxidative cleavage to the acid, an alkylated C-sugar, appropriate for attachment to peptides or other drug candidates for solubility enhancement. 8 Mg of leucine attached to I could be completely dissolved in 1 mL of ether, while leucine itself is insol. in ether. 6 Mg of leucine could not be dissolved in 0.25 mL of distilled water while 12 mg of leucine attached to the acid derivative was completely soluble in the same amount of water. With the bioconjugate attached, leucine water solubility was increased to at least 48 mg/mL; leucine itself is soluble only to 23 mg/mL.

IT 603131-28-8
RL: FMU (Formation, unclassified); PRP (Properties); FORM (Formation,


nonpreparative)

(synthesis of permethylated mannosyl-acetic acid as a new type of
bio-conjugate from mannopyranoside via stereoselective allylation and
oxidative bond cleavage)

RN 603131-28-8 CAPLUS

CN L-Leucine, N-(3,7-anhydro-2-deoxy-4,5,6,8-tetra-O-methyl-D-glycero-D-talo-
octonoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 17 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:826257 CAPLUS

DN 138:170449

TI Synthesis of sugar azido or amino esters and their use as building blocks
for the preparation of saccharide nucleosides

AU Xie, Juan

CS Universite Pierre et Marie Curie, Laboratoire de Chimie des Glucides, UMR
7613, Paris, 75005, Fr.

SO European Journal of Organic Chemistry (2002), (20), 3411-3418

CODEN: EJOCFK; ISSN: 1434-193X

PB Wiley-VCH Verlag GmbH & Co. KGaA

DT Journal

LA English

OS CASREACT 138:170449

AB Several sugar azido or amino esters bearing an α - or a
 β -C-D-glucopyranosyl backbone have been prepared by
TMSOTf/Ac₂O-mediated α -C-glycosylation with concurrent selective
removal of the primary benzyl group or selective acetolysis of the primary
benzyl group of β -C-glycoside as key steps. Such structures have
been successfully used as scaffolds for the synthesis of novel saccharide
nucleosides.


IT 497227-05-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of sugar azido or amino esters and their use as building
blocks for prepn. of saccharide nucleosides via
C-glycosylation and regioselective acetolysis)

RN 497227-05-1 CAPLUS

CN Uridine, 5'-[[8-[[5-(acetylamino)-2,6-anhydro-5,7,8-trideoxy-1,3,4-tris-O-
(phenylmethyl)-D-glycero-L-gulo-octitol-8-yl]amino]-2,6-anhydro-7,8-
dideoxy-8-oxo-3,4,5-tris-O-(phenylmethyl)-L-glycero-L-gulo-octonoyl]amino]-
5'-deoxy-2',3'-bis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



— Ph

— Ph

RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 18 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:716289 CAPLUS
DN 137:232918
TI Helicomicmetics and stabilized LXXLL peptidomimetics
IN Spatola, Arno F.; Leduc, Anne-Marie
PA University of Louisville, USA
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072597	A2	20020919	WO 2002-US7093	20020311
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005054770 A1 20050310 US 2004-471120 20040923

PRAI US 2001-274846P P 20010309

WO 2002-US7093 W 20020311

OS MARPAT 137:232918

AB A helicomicetic compound for stabilizing the α -helical structure of a protein fragment, which can serve as an agonist or antagonist of protein-protein interactions, comprises a compound of structure R1-(Xn)-D-Cys-Y-Y-L-Cys-(Xn)-R2 [R1 is H, an alkyl, aryl, acetyl, formyl, or other blocking or solubilizing group, such as a polyethylene glycol (PEG) or other polyether moiety, linked to the N-terminal nitrogen through a carbon-nitrogen bond; X is one or more natural or unnatural amino acids, linked together in a chain from 0 to n in length; Y is a natural or unnatural amino acid, usually of the L-configuration, and with two such amino acids that need not be identical, separating the pairs of cysteines to form an i to i + 3 type of disulfide bridged unit; R2 is OH, NH₂, NHR, OR, or other blocking or solubilizing group, such as polyethylene glycol (PEG) or other polyether moiety, linked to the C-terminal carbonyl through an oxygen or carbon or nitrogen linkage, such as an amide group]. The invention includes helix-stabilized compds. that contain the so-called NR Box found in a large number of Nuclear Receptor Coactivator Proteins. The NR Box sequence, consisting of Leu-Xxx-Yyy-Leu-Leu within a longer peptide, is found in both coactivator proteins and also in certain nuclear receptors. The Boc-based Merrifield solid-phase method was used to prepare linear and cyclic peptides, including H-Lys-His-Lys-Ile-Leu-His-Arg-Leu-Leu-Gln-Asp-Ser-Ser-OH (AML-I-89/2) and H-D-Lys-cyclo(D-Cys-Ile-Leu-Cys)-Arg-Leu-Leu-Gln-NH₂ (AKG-I-28). Ki values are tabulated for the peptides against estrogen receptors (ER) alpha and beta. Short linear peptides that contain the LXXLL sequence, such as Leu-Asn-Gln-Leu-Leu, do not display any inhibitory activity with respect to the desired effect of inhibiting the binding of the estrogen receptors to the helical segment of coactivator proteins. Compds. that contain a D-Cys, L-Cys pairing are especially active with respect to binding inhibition.

IT 459844-33-8P, AML-I-31


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of α -helix stabilized LXXLL peptidomimetics)

RN 459844-33-8 CAPLUS


CN L-Leucine, N-(3,7-anhydro-2-deoxy-D-manno-octonoyl)-L-leucyl-L- α -glutamyl-L-glutaminy-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



TI Preparation of alkylated C-glycoside glycopeptides
 IN Spatola, Arno F.; Taylor, K. Grant; Brunel, Florence
 PA University of Louisville, USA
 SO PCT Int. Appl., 24 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002072593	A2	20020919	WO 2002-US7092	20020311
	WO 2002072593	A3	20030313		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005059814	A1	20050317	US 2004-471328	20041026
PRAI	US 2001-274860P	P	20010309		
	WO 2002-US7092	W	20020311		
OS	MARPAT 137:217246				
GI					



AB The present invention relates to alkylated C-glycoside glycopeptides which are new carbohydrate derivs. based on the "C-Sugar" platform. These alkylated C-sugars are converted from hydrophilic, hydrogen-bonded saccharide derivs. and are very stable, highly soluble and relatively low mol. weight structures. These alkylated C-sugars can serve as effective bio-conjugates and pharmaceutical carriers. The alkylated C-sugar have the formula I, wherein X = (CH₂OR)_n; n = 0-4; R = aryl, alkyl, or halogen-substituted aryl or alkyl, Y = (CH₂)_mNH₂, (CH₂)_mCO₂H, (CH₂)_mOH, (CH₂)_mCHO, (CH₂)_mCl, and m = 0-3.

IT 457617-62-8P



RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of alkylated C-glycoside glycopeptides)

RN 457617-62-8 CAPLUS

CN L-Glutamamide, N2-(3,7-anhydro-2-deoxy-4,5,6,8-tetra-O-methyl-D-glycero-D-talo-octonoyl)-L-lysyl-D-cysteinyl-L-isoleucyl-L-leucyl-L-cysteinyl-L-arginyl-L-leucyl-L-leucyl-, cyclic (2→5)-disulfide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 20 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:692298 CAPLUS
 DN 138:385694
 TI Expanding diversity: modification of linear and cyclic peptides by
 C-glycosylation and N-methylation
 AU Brunel, Florence; Leduc, Anne-Marie; Singh, Sujana; Tang, Xiaoping; Vogel,
 David M.; Taylor, K. Grant; Spatola, Arno F.
 CS Department of Chemistry and The Institute for Molecular Diversity and Drug
 Design, University of Louisville, Louisville, KY, 40292, USA
 SO Peptides: The Wave of the Future, Proceedings of the Second International
 and the Seventeenth American Peptide Symposium, San Diego, CA, United

States, June 9-14, 2001 (2001), 170-171. Editor(s): Lebl, Michal; Houghten, Richard A. Publisher: American Peptide Society, San Diego, Calif.

CODEN: 69DBAL; ISBN: 0-9715560-0-8

DT Conference

LA English

AB A symposium report. Several pseudoglycopeptides were synthesized through N-methylation and the introduction of C-glycosides.


IT 528598-56-3P 528598-60-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of pseudoglycopeptides by C-glycosylation and N-methylation)

RN 528598-56-3 CAPLUS

CN L-Leucine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-L-leucyl-L- α -glutamyl-L-glutamyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 528598-60-9 CAPLUS



CN L-Leucine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-L-leucyl-3-(2-naphthalenyl)alanyl- ψ (CH₂-NH)-L-glutamyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 21 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:623042 CAPLUS
 DN 138:14142
 TI Synthesis of a 56 component library of sugar β -peptides
 AU Lohse, Anders; Schweizer, Frank; Hindsgaul, Ole
 CS Department of Chemistry, University of Aarhus, Aarhus C., DK-8000, Den.
 SO Combinatorial Chemistry and High Throughput Screening (2002), 5(5),
 389-394
 CODEN: CCHSFU; ISSN: 1386-2073
 PB Bentham Science Publishers
 DT Journal
 LA English
 OS CASREACT 138:14142
 GI



AB Many biol. processes of vital importance are triggered by the mol. recognition of small carbohydrate units by proteins and receptors thus leading to the belief that carbohydrates could act as candidates for the design of new drugs. We have developed a new useful synthetic approach, which can be applied in a combinatorial manner, giving access to 1,1-di-substituted pyrans projecting amide side chains in both the α - and β -directions. Thus, treatment of the readily accessible hemiketal (I) with TFA followed by trimethylsilyl trifluoromethanesulfonate (TMSOTf) in the presence of a nitrile gives dihydrooxazinones (II) via a new type of modified intramol. Ritter reaction. The dihydrooxazinones can either be isolated or used directly in reactions with a broad variety of amines. Final deprotection furnishes the 1,1-di-substituted sugar β -peptides having the general structure (III).

IT 477718-63-1P 477718-64-2P 477718-65-3P
 477718-66-4P 477718-67-5P 477718-68-6P
 477718-70-0P 477718-71-1P 477718-72-2P
 477718-73-3P 477718-77-7P 477718-78-8P


477718-79-9P 477718-80-2P 477718-81-3P
 477718-82-4P 477718-84-6P 477718-85-7P
 477718-86-8P 477718-87-9P 477718-91-5P
 477718-92-6P 477718-93-7P 477718-94-8P
 477718-95-9P 477718-96-0P 477718-98-2P
 477718-99-3P 477719-00-9P 477719-01-0P
 477801-13-1P 477801-14-2P 477801-15-3P
 477801-16-4P 477801-17-5P 477801-18-6P
 477801-20-0P 477801-21-1P 477801-22-2P
 477801-23-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of sugar β -peptides combinatorial library using
 intramol. Ritter addition)

RN 477718-63-1 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-2,3-dideoxy-N-1-
 piperidiny- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477718-64-2 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-N-cyclobutyl-
 2,3-dideoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477718-65-3 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-N-cyclopentyl-
 2,3-dideoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477718-66-4 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-N-cyclohexyl-2,3-dideoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477718-67-5 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-N-cycloheptyl-2,3-dideoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477718-68-6 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-2,3-dideoxy-N-[[[(1S,2R)-2-hydroxycyclohexyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477718-70-0 CAPLUS

CN Glycine, N-[3-(benzoylamino)-2,3-dideoxy- α -D-galacto-3-octulopyranosonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477718-71-1 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, N-(2-aminoethyl)-3-(benzoylamino)-2,3-dideoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477718-72-2 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-2,3-dideoxy-N-[2-hydroxy-1-(hydroxymethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477718-73-3 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-2,3-dideoxy-N-octyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477718-77-7 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-N-1-piperidinyl-3-[[1,2,3,4-tetrahydro-1-naphthalenyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477718-78-8 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, N-cyclobutyl-2,3-dideoxy-3-[[1,2,3,4-tetrahydro-1-naphthalenyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477718-79-9 CAPLUS

CN α-D-galacto-3-Octulopyranosonamide, N-cyclopentyl-2,3-dideoxy-3-
[[[(1,2,3,4-tetrahydro-1-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 477718-80-2 CAPLUS

CN α-D-galacto-3-Octulopyranosonamide, N-cyclohexyl-2,3-dideoxy-3-
[[[(1,2,3,4-tetrahydro-1-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 477718-81-3 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, N-cycloheptyl-2,3-dideoxy-3-
[[[(1,2,3,4-tetrahydro-1-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 477718-82-4 CAPLUS


CN α -D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-N-[[[(1S,2R)-2-
hydroxycyclohexyl]methyl]-3-[[[(1,2,3,4-tetrahydro-1-
naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Chemical structure of a complex molecule, likely a derivative of a natural product, showing a bicyclic system (naphthalene-like) fused to a six-membered ring. The structure is labeled with 'R' and 'S' stereochemistry.


Absolute stereochemistry.



RN 477718-86-8 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-N-[2-hydroxy-1-(hydroxymethyl)ethyl]-3-[[[(1,2,3,4-tetrahydro-1-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477718-87-9 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-N-octyl-3-[[[(1,2,3,4-tetrahydro-1-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477718-91-5 CAPLUS

CN α-D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-N-1-piperidinyl-3-
[[[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 477718-92-6 CAPLUS

CN α-D-galacto-3-Octulopyranosonamide, N-cyclobutyl-2,3-dideoxy-3-
[[[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 477718-93-7 CAPLUS

CN α-D-galacto-3-Octulopyranosonamide, N-cyclopentyl-2,3-dideoxy-3-
[[[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 477718-94-8 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, N-cyclohexyl-2,3-dideoxy-3-
[[[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 477718-95-9 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, N-cycloheptyl-2,3-dideoxy-3-
[[[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 477718-96-0 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-N-[[[(1S,2R)-2-
hydroxycyclohexyl]methyl]-3-[[[(1,2,3,4-tetrahydro-2-
naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477718-98-2 CAPLUS

CN Glycine, N-[2,3-dideoxy-3-[[[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]amino]-α-D-galacto-3-octulopyranosonoyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477718-99-3 CAPLUS

CN α-D-galacto-3-Octulopyranosonamide, N-(2-aminoethyl)-2,3-dideoxy-3-[[[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477719-00-9 CAPLUS

CN α-D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-N-[2-hydroxy-1-(hydroxymethyl)ethyl]-3-[[[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477719-01-0 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-N-octyl-3-[[[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477801-13-1 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-3-[[[(1,2,3,4,4a,9,10,10a-octahydro-9-phenanthrenyl)carbonyl]amino]-N-1-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477801-14-2 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, N-cyclobutyl-2,3-dideoxy-3-[[[(1,2,3,4,4a,9,10,10a-octahydro-9-phenanthrenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477801-15-3 CAPLUS

CN α-D-galacto-3-Octulopyranosonamide, N-cyclopentyl-2,3-dideoxy-3-
[[[(1,2,3,4,4a,9,10,10a-octahydro-9-phenanthrenyl) carbonyl] amino] - (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 477801-16-4 CAPLUS

CN α-D-galacto-3-Octulopyranosonamide, N-cyclohexyl-2,3-dideoxy-3-
[[[(1,2,3,4,4a,9,10,10a-octahydro-9-phenanthrenyl) carbonyl] amino] - (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 477801-17-5 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, N-cycloheptyl-2,3-dideoxy-3-
[[[(1,2,3,4,4a,9,10,10a-octahydro-9-phenanthrenyl)carbonyl]amino]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 477801-18-6 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-N-[[[(1S,2R)-2-
hydroxycyclohexyl]methyl]-3-[[[(1,2,3,4,4a,9,10,10a-octahydro-9-
phenanthrenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477801-20-0 CAPLUS

CN Glycine, N-[2,3-dideoxy-3-[[[(1,2,3,4,4a,9,10,10a-octahydro-9-phenanthrenyl)carbonyl]amino]- α -D-galacto-3-octulopyranosonyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477801-21-1 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, N-(2-aminoethyl)-2,3-dideoxy-3-[[[(1,2,3,4,4a,9,10,10a-octahydro-9-phenanthrenyl)carbonyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477801-22-2 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-N-[2-hydroxy-1-

(hydroxymethyl)ethyl]-3-[[[(1,2,3,4,4a,9,10,10a-octahydro-9-phenanthrenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477801-23-3 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-3-[[[(1,2,3,4,4a,9,10,10a-octahydro-9-phenanthrenyl)carbonyl]amino]-N-octyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 22 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:457030 CAPLUS

DN 137:263245

TI Preparation of glycosyl amino acids as building blocks for the combinatorial synthesis of neoglycoconjugates

AU Ziegler, Thomas; Roseling, Dirk; Subramanian, Lakshminarayananapuram R.

CS Institute of Organic Chemistry, University of Tübingen, Tübingen, D-72076, Germany

SO Tetrahedron: Asymmetry (2002), 13(9), 911-914

CODEN: TASYE3; ISSN: 0957-4166

PB Elsevier Science Ltd.

DT Journal

LA English

OS CASREACT 137:263245

AB Several neoglycosyl amino acids possessing a sugar residue, a spacer and a trifunctional amino acid moiety were synthesized both in solution and solid

phase by activating the carboxylic group as its pentafluorophenyl ester for condensation. The methodol. is useful for application in combinatorial syntheses of neoglycoconjugates as potential mimics for oligosaccharides.

IT 463313-68-0P

RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)


(prepn. of glycosyl amino acids as chiral synthons for the combinatorial synthesis of neoglycoconjugates and oligosaccharide mimics)

RN 463313-68-0 CAPLUS


CN L-Alanine, N-[5-(α -D-mannopyranosyloxy)pentyl]-L- α -asparaginyl-N-[5-(β -D-glucopyranosyloxy)pentyl]-L- α -asparaginyl-N-[5-(β -D-galactopyranosyloxy)pentyl]-L- α -asparaginyl-N6-(3,7-anhydro-2-deoxy-D-glycero-D-gulo-octonoyl)-D-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



IT 463313-65-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. of glycosyl amino acids as chiral synthons for the
 combinatorial synthesis of neoglycoconjugates and oligosaccharide
 mimics)
 RN 463313-65-7 CAPLUS
 CN L-Lysine, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-N6-(4,5,6,8-tetra-O-acetyl-
 3,7-anhydro-2-deoxy-D-glycero-D-gulo-octonoyl)-, pentafluorophenyl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 23 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:182735 CAPLUS
 DN 136:340919
 TI β -C-Mannosides as Selectin Inhibitors
 AU Kaila, Neelu; Chen, Lihren; Thomas, Bert E. , IV; Tsao, Desiree; Tam,
 Steve; Bedard, Patricia W.; Camphausen, Raymond T.; Alvarez, Juan C.;
 Ullas, Giliyar
 CS Departments of Chemical Sciences, Biological Chemistry, and Immunology &
 Hemostasis, Wyeth Research, Cambridge, MA, 02140, USA
 SO Journal of Medicinal Chemistry (2002), 45(8), 1563-1566
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 136:340919
 AB Potential E- and P-selectin inhibitors were synthesized to explore a
 hydrophobic area on the E-selectin surface and the PSGL-1 protein binding
 site on the P-selectin surface that was recently defined by crystallog.
 Three series of mannose-based compds. (libraries A, B, and C) were
 synthesized using solution phase parallel synthesis. Biol. evaluation of
 these compds. was done using two ELISA-based assays and transferred NOE
 (trNOE) expts. Some of the compds. showed better activity than sLex in
 the P-selectin assay.
 IT 418771-21-8P
 RL: BSU (Biological study, unclassified); CPN (Combinatorial preparation);
 BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation)
 (combinatorial prepn. of β -C-mannosides as selectin

inhibitors)

RN 418771-21-8 CAPLUS

CN Pentanoic acid, 4-[(3,7-anhydro-2-deoxy-D-glycero-D-galactooctonoyl)amino]-5-oxo-5-[[2-[5-(phenylmethoxy)-1H-indol-3-yl]ethyl]amino]-, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 330955-04-9P

RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(combinatorial prepn. of β -C-mannosides as selectin inhibitors)

RN 330955-04-9 CAPLUS

CN Benzenebutanoic acid, 4-[(3,7-anhydro-2-deoxy-D-glycero-D-galactooctonoyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 418771-13-8P

RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)
(combinatorial prepn. of β -C-mannosides as selectin inhibitors)

RN 418771-13-8 CAPLUS

CN L-Asparagine, N-(3,7-anhydro-2-deoxy-D-glycero-D-galactooctonoyl)-L- α -glutamyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 24 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:51484 CAPLUS
DN 136:102620
TI Preparation of glycopyranoside phosphates for treatment of T
lymphocyte mediated inflammatory diseases
IN Cowden, William Butler; Eschler, Bart Michael; March, Darren Ray; Francis,
Douglas John; Gerba, Sendaba; Bartell, Gavin James; Charlton, Brett
PA Praxis Pharmaceuticals Pty. Ltd., Australia
SO PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002004472	A1	20020117	WO 2001-AU831	20010711
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2415214	A1	20020117	CA 2001-2415214	20010711
EP 1301522	A1	20030416	EP 2001-949109	20010711
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004501985	T	20040122	JP 2002-509335	20010711
NZ 523565	A	20040326	NZ 2001-523565	20010711
US 2003176363	A1	20030918	US 2003-338679	20030109
US 6878690	B2	20050412		
PRAI AU 2000-8723	A	20000711		
WO 2001-AU831	W	20010711		
OS MARPAT 136:102620				
GI				




AB Glycopyranoside phosphates I, wherein R is H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cyano, hydroxytetrahydropyranyloxyalkyl and $(CH_2)_nCOX$, wherein n represents an integer from 0 to 20 inclusive and X is independently selected from Y, OY' and NY''Y''' wherein Y is independently selected from H, alkyl, alkenyl, alkynyl aryl, heteroaryl, aralkyl, heteroaralkyl, carbohydrate and Y' is independently selected from H, alkyl, alkenyl, alkynyl aryl, heteroaryl aralkyl, heteroaralkyl, and carbohydrate Y'' and Y''' are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl aralkyl, heteroaralkyl or acyl wherein each of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl and acyl may be optionally substituted, and the use thereof in treating diseases or conditions that are dependent on T-lymphocyte migration, as well as compns. containing said compds. Thus, phosphoric acid mono[6-(3-hexyloxypropyl)-3,4,5-trihydroxy-tetrahydropyran-2-yl-methyl] ester sodium salt was prepared Title glycosides may be used for treating diseases such as rheumatoid arthritis, multiple sclerosis, acute disseminated encephalomyelitis, psoriasis, Crohn's disease, T cell-mediated dermatitis, stromal keratitis, uveitis, thyroiditis, sialitis or type I diabetes.

IT 388593-58-6P 388593-75-7P 388593-81-5P
 RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of glycopyranoside phosphates for treatment of T-lymphocyte mediated inflammatory diseases)

RN 388593-58-6 CAPLUS
 CN L-Phenylalanine, N-[(3ξ)-3,7-anhydro-2-deoxy-8-O-phosphono-D-manno-octonoyl]-, monosodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Na

RN 388593-75-7 CAPLUS
 CN L-Glutamic acid, N-[(3ξ)-3,7-anhydro-2-deoxy-8-O-phosphono-D-manno-octonoyl]-, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 Na

RN 388593-81-5 CAPLUS

CN D-manno-Octonamide, 3,7-anhydro-2-deoxy-N-(2-phenylethyl)-, 8-(dihydrogen phosphate), monosodium salt, (3ξ)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

IT 388593-61-1P 388593-62-2P 388593-63-3P

388593-64-4P 388593-78-0P 388593-79-1P

388593-80-4P


RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of glycopyranoside phosphates for treatment of T-lymphocyte mediated inflammatory diseases)

RN 388593-61-1 CAPLUS

CN L-Phenylalanine, N-[(3ξ)-4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-manno-octonoyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388593-62-2 CAPLUS

CN L-Phenylalanine, N-[(3ξ)-3,7-anhydro-2-deoxy-D-manno-octonoyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388593-63-3 CAPLUS

CN L-Phenylalanine, N-[(3ξ)-4,5,6-tri-O-acetyl-3,7-anhydro-2-deoxy-8-O-(triphenylmethyl)-D-manno-octonoyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388593-64-4 CAPLUS

CN L-Phenylalanine, N-[(3ξ)-4,5,6-tri-O-acetyl-3,7-anhydro-2-deoxy-D-manno-octonoyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388593-78-0 CAPLUS


CN L-Glutamic acid, N-[(3ξ)-3,7-anhydro-2-deoxy-4,5,6-tris-O-(phenylmethyl)-D-manno-octonoyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388593-79-1 CAPLUS
 CN L-Glutamic acid, N-[(3ξ)-3,7-anhydro-2-deoxy-4,5,6-tris-O-(phenylmethyl)-8-O-phosphono-D-manno-octonoyl]-, 1,5-[bis(phenylmethyl)] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388593-80-4 CAPLUS
 CN L-Glutamic acid, N-[(3ξ)-3,7-anhydro-2-deoxy-8-O-phosphono-D-manno-octonoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 25 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2001:841083 CAPLUS
 DN 136:134978
 TI Chain Extension of Sugar δ-Lactones with the Enolate of tert-Butyl Bromoacetate and Elaboration into Functionalized C-Ketosides, C-Glycosides, and C-Glucosyl Glycines
 AU Schweizer, Frank; Inazu, Toshiyuki
 CS Noguchi Institute, Tokyo, 173-0003, Japan
 SO Organic Letters (2001), 3(25), 4115-4118
 CODEN: ORLEF7; ISSN: 1523-7060

PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 136:134978
 GI



AB We describe the synthesis of a series of exocyclic sugar epoxides I prepared in a one-step procedure from sugar δ -lactones with the enolate of tert-Bu bromoacetate. Ring opening of the sugar oxiranes provides C-ketosides while reduction affords functionalized C-glycosides bearing an α -hydroxy ester moiety. The α -hydroxy ester can be converted into C-glucosyl glycine analogs II.


IT 391658-62-1P 391658-63-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (chain extension of sugar δ -lactones with the enolate of tert-Bu bromoacetate and elaboration into functionalized C-ketosides, C-glycosides and C-glucosyl glycines)

RN 391658-62-1 CAPLUS

CN D-erythro-L-talo-Octonamide, 2-amino-3,7-anhydro-2-deoxy-N-(phenylmethyl) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 391658-63-2 CAPLUS

CN D-erythro-L-talo-Octonamide, 3,7-anhydro-2-(cyclohexylamino)-2-deoxy-N-(phenylmethyl) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 26 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:675317 CAPLUS
DN 136:53963
TI One pot conversion of ketoses into sugar β -peptides via a Ritter reaction
AU Schweizer, Frank; Lohse, Anders; Otter, Albin; Hindsgaul, Ole
CS Department of Chemistry, University of Alberta, Edmonton, AB, T6G 2G2, Can.
SO Synlett (2001), (9), 1434-1436
CODEN: SYNLES; ISSN: 0936-5214
PB Georg Thieme Verlag
DT Journal
LA English
OS CASREACT 136:53963
AB α -D-Galacto-2-deoxy-oct-3-ulopyranosonic acids can be converted into unnatural glycopeptides via a one pot intramol. Ritter reaction. Initially, the ketopyranoside reacts under Lewis acid catalyzed conditions with a nitrile (aromatic or aliphatic) to form a glycosylimino anhydride intermediate which can be isolated. Exposure of this intermediate to simple primary amines or amino acids produces novel sugar- β -peptides. Three different nitriles and three different amines have been used to generate 6 sugar β -peptides to demonstrate the generality of this reaction.
IT 381724-80-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of sugar β -peptides via one-pot intramol. Ritter reaction)
RN 381724-80-7 CAPLUS
CN α -D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-2,3-dideoxy-N-(phenylmethyl)-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 381724-77-2P 381724-78-3P 381724-79-4P
 381724-81-8P 381724-82-9P 381724-83-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of sugar β -peptides via one-pot intramol. Ritter
 reaction)
 RN 381724-77-2 CAPLUS
 CN α -D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-N-cycloheptyl-
 2,3-dideoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 381724-78-3 CAPLUS
 CN Glycine, N-[3-(acetylamino)-2,3-dideoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-
 α -D-galacto-3-octulopyranosonoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 381724-79-4 CAPLUS
 CN α -D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-3-(acetylamino)-N-
 (phenylmethyl)-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381724-81-8 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, N-cycloheptyl-2,3-dideoxy-3-
[(phenylacetyl)amino]-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 381724-82-9 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-3-
[(phenylacetyl)amino]-N-(phenylmethyl)-4,5,6,8-tetrakis-O-(phenylmethyl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381724-83-0 CAPLUS

CN α -D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-2,3-dideoxy-N-
(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 27 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2001:601763 CAPLUS
 DN 135:331663
 TI A General Synthesis of Structurally Diverse Building Blocks for Preparing Analogues of C-Linked Antifreeze Glycoproteins
 AU Eniade, Adewale; Murphy, Anastasia V.; Landreau, Geraldine; Ben, Robert N.
 CS Department of Chemistry, State University of New York at Binghamton, Binghamton, NY, 13902, USA
 SO Bioconjugate Chemistry (2001), 12(5), 817-823
 CODEN: BCCHES; ISSN: 1043-1802
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 135:331663
 AB A synthetic methodol. to afford unusual glycoconjugate building blocks useful for the solid-phase synthesis of C-linked antifreeze glycoprotein (AFGP) analogs is described. Such compds. are urgently required in order to elucidate the mol. mechanism by which AFGPs function. All reactions are general in nature and accommodate structural variation in the carbohydrate moiety, polypeptide backbone, and amino acid side chain.
 IT 369649-14-9P 369649-16-1P 369649-17-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of glycopeptide building blocks that can be useful for the solid-phase synthesis of C-linked antifreeze glycoprotein analogs)
 RN 369649-14-9 CAPLUS
 CN L-Alanine, N6-[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-[(1,1-dimethylethyl)dimethylsilyl]-D-glycero-L-gluco-octonoyl]-N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-lysyl-L-alanyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




Bu-t




RN 369649-16-1 CAPLUS
 CN Glycine, N6-[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-[(1,1-dimethylethyl)dimethylsilyl]-D-glycero-L-gluco-octonoyl]-N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-lysyl-L-prolyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 369649-17-2 CAPLUS
 CN Glycine, N5-[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-[(1,1-dimethylethyl)dimethylsilyl]-D-glycero-L-gluco-octonoyl]-N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-ornithylglycyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 28 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:208811 CAPLUS
DN 134:353532
TI Fully Convergent Solid Phase Synthesis of Antifreeze Glycoprotein Analogues
AU Eniade, Adewale; Ben, Robert N.
CS Department of Chemistry, State University of New York, Binghamton, NY, 13902, USA
SO Biomacromolecules (2001), 2(2), 557-561
CODEN: BOMAF6; ISSN: 1525-7797
PB American Chemical Society
DT Journal
LA English
OS CASREACT 134:353532
AB The convergent solid phase synthesis of C-linked analogs of antifreeze glycoprotein (AFGP) has been achieved. In this approach, three to six carbohydrate residues are simultaneously coupled to a resin-bound polypeptide. Glycopeptides ranging from 1.6 to 3.0 kDa are easily prepared in 26-44% yield demonstrating the utility of this approach.
IT 339149-38-1P 339149-39-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of antifreeze glycoprotein analogs using convergent solid phase synthesis techniques)
RN 339149-38-1 CAPLUS
CN Glycine, N-acetylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluc-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluc-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluc-octonoyl)-L-lysylglycylglycyl-, hydrazide (9CI) (CA INDEX NAME)



Absolute stereochemistry.





RN 339149-39-2 CAPLUS



CN Glycine, N-acetylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluc-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluc-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluc-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluc-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluc-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluc-octonoyl)-L-lysylglycylglycyl-, hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.





HO



RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 29 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2000:125930 CAPLUS
 DN 132:322131
 TI Glycomimetics: A Programmed Approach toward Neoglycopeptide Libraries
 AU Arya, Prabhat; Kutterer, Kristina M. K.; Barkley, Angela
 CS Chemical Biology Program, Steacie Institute for Molecular Sciences,
 National Research Council of Canada, Ottawa, ON, K1A 0R6, Can.
 SO Journal of Combinatorial Chemistry (2000), 2(2), 120-126
 CODEN: JCCHFF; ISSN: 1520-4766
 PB American Chemical Society
 DT Journal
 LA English
 AB A programmed synthesis of neoglycopeptides has been developed in which
 two, similar or different, glycoside moieties could be attached either (i)
 at the N-terminal of short peptides or (ii) one at the N-terminal and the
 other(s) at the N-terminal site, in a highly flexible and controlled
 manner. A stepwise branching of N-terminal peptides has been achieved by
 glycoside aldehyde reductive amination followed by the glycoside
 carboxylic acid coupling. In another approach, after N-alkylation with
 glycoside aldehyde, the N-glycosylated derivative is subjected to peptide
 synthesis. This is then followed by the attachment of the second
 glycoside moiety at the N-terminal using either glycoside aldehyde or
 glycoside carboxylic acid derivative. Alternatively, the attachment of second
 and third glycoside derivs. could be achieved simultaneously, by reductive
 amination/carboxylic acid couplings. The methodologies presented here are
 highly versatile and combine diversity in both peptides/pseudopeptides and
 glycoside moieties.
 IT 193156-93-3P 267234-65-1P 267234-66-2P
 267234-67-3P 267234-68-4P 267234-69-5P
 267234-70-8P 267234-71-9P 267234-72-0P
 267234-73-1P 267234-74-2P 267234-75-3P


267234-76-4P 267234-77-5P 267234-78-6P
 267234-79-7P 267234-80-0P 267234-81-1P
 267234-82-2P 267234-83-3P 267234-84-4P
 267234-85-5P 267234-86-6P 267234-87-7P
 267234-88-8P 267234-89-9P 267234-90-2P
 267234-91-3P 267234-92-4P 267234-93-5P
 267234-94-6P 267234-95-7P 267234-96-8P
 267234-97-9P 267234-98-0P 267234-99-1P
 267235-00-7P 267235-01-8P 267235-02-9P
 267235-09-6P 267235-10-9P 267235-11-0P
 267235-12-1P 267235-13-2P 267235-14-3P
 267235-15-4P 267235-16-5P 267235-17-6P
 267235-18-7P 267235-19-8P 267235-20-1P
 267235-21-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of neoglycopeptide libraries for use as
 glycomimetics)

RN 193156-93-3 CAPLUS

CN Glycine, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-
 octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-
 galacto-octitol-8-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-65-1 CAPLUS

CN D-glycero-L-galacto-Octitol, 8-[(2-amino-2-oxoethyl) (4,5,6,8-tetra-O-
 acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl) amino]-2,6-anhydro-
 7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-66-2 CAPLUS

CN L-glycero-L-galacto-Octitol, 8-[(2-amino-2-oxoethyl) (4,5,6,8-tetra-O-
 acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl) amino]-2,6-anhydro-
 7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-67-3 CAPLUS

CN D-glycero-L-gulo-Octitol, 8-[(2-amino-2-oxoethyl) (4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl) amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-68-4 CAPLUS

CN D-glycero-L-galacto-Octitol, 8-[[[(1S)-2-amino-1-methyl-2-oxoethyl] (4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl) amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 267234-69-5 CAPLUS

CN L-glycero-L-galacto-Octitol, 8-[[[(1S)-2-amino-1-methyl-2-oxoethyl] (4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl) amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-70-8 CAPLUS

CN D-glycero-L-gulo-Octitol, 8-[[[(1S)-2-amino-1-methyl-2-oxoethyl] (4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl) amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-71-9 CAPLUS

CN D-glycero-L-galacto-Octitol, 8-[[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl] (4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl) amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-72-0 CAPLUS

CN L-glycero-L-galacto-Octitol, 8-[[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl] (4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl) amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-73-1 CAPLUS

CN D-glycero-L-gulo-Octitol, 8-[[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl] (4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl) amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-74-2 CAPLUS

CN L-glycero-L-galacto-Octitol, 8-[(2-amino-2-oxoethyl) (4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-manno-octonoyl) amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-75-3 CAPLUS

CN L-Alanine, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-glucopyranosyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galactooctitol-8-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-76-4 CAPLUS

CN L-Phenylalanine, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-glucopyranosyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galactooctitol-8-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-77-5 CAPLUS

CN D-glycero-L-gulo-Octitol, 8-[[[(1S)-2-amino-1-methyl-2-oxoethyl](4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-78-6 CAPLUS

CN D-glycero-D-gulo-Octitol, 1-[[[(1S)-2-amino-1-methyl-2-oxoethyl] (4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)amino]-3,7-anhydro-1,2-dideoxy-, 4,5,6,8-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-79-7 CAPLUS

CN D-glycero-D-manno-Octitol, 8-[[[(1S)-2-amino-1-methyl-2-oxoethyl] (4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-80-0 CAPLUS

CN D-glycero-D-manno-Octitol, 8-[[[(1S)-2-amino-1-methyl-2-oxoethyl] (4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-81-1 CAPLUS

CN D-glycero-L-gulo-Octitol, 8-[[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl] (4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-82-2 CAPLUS

CN D-glycero-D-gulo-Octitol, 1-[[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl] (4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)amino]-3,7-anhydro-1,2-dideoxy-, 4,5,6,8-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-83-3 CAPLUS

CN D-glycero-D-manno-Octitol, 8-[[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl] (4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 267234-84-4 CAPLUS

CN D-glycero-D-manno-Octitol, 8-[[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl] (4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-85-5 CAPLUS

CN D-glycero-L-gulo-Octitol, 8-[[[(1S)-1-(aminocarbonyl)-3-methylbutyl] (4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-86-6 CAPLUS

CN D-glycero-D-gulo-Octitol, 1-[[[(1S)-1-(aminocarbonyl)-3-methylbutyl] (4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl) amino]-3,7-anhydro-1,2-dideoxy-, 4,5,6,8-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-87-7 CAPLUS

CN D-glycero-D-manno-Octitol, 8-[[[(1S)-1-(aminocarbonyl)-3-methylbutyl] (4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl) amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 267234-88-8 CAPLUS

CN D-glycero-D-manno-Octitol, 8-[[[(1S)-1-(aminocarbonyl)-3-methylbutyl] (4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-

octonoyl) amino] -2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-89-9 CAPLUS

CN L-Alaninamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl) -N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)glycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-90-2 CAPLUS

CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl) -N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-91-3 CAPLUS

CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-92-4 CAPLUS

CN Glycine, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-93-5 CAPLUS

CN Glycine, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluc-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-94-6 CAPLUS

CN Glycine, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluc-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-95-7 CAPLUS

CN L-Alaninamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-96-8 CAPLUS

CN L-Alaninamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-97-9 CAPLUS

CN L-Alaninamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-octitol-8-yl)-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-98-0 CAPLUS

CN L-Alaninamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-octitol-8-yl)-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267234-99-1 CAPLUS

CN L-Leucinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267235-00-7 CAPLUS

CN L-Leucinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267235-01-8 CAPLUS

CN L-Leucinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-octitol-8-yl)-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267235-02-9 CAPLUS

CN L-Leucinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-octitol-8-yl)-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267235-09-6 CAPLUS


CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)-L-phenylalanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 267235-10-9 CAPLUS
 CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-L-phenylalanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 267235-11-0 CAPLUS
 CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)-L-phenylalanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267235-12-1 CAPLUS
 CN L-Alaninamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)-L-phenylalanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267235-13-2 CAPLUS

CN L-Alaninamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-L-phenylalanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-octitol-8-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267235-14-3 CAPLUS

CN L-Alaninamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)-L-phenylalanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 267235-15-4 CAPLUS

CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-

octonoyl)-L-alanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267235-16-5 CAPLUS

CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-L-alanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-octitol-8-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267235-17-6 CAPLUS

CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)-L-alanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-octitol-8-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267235-18-7 CAPLUS

CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-glucopyranosyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)-L-alanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267235-19-8 CAPLUS

CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-glucopyranosyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)-L-alanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267235-20-1 CAPLUS

CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-glucopyranosyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)-L-alanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 267235-21-2 CAPLUS

CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-glucopyranosyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)-L-alanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)- (9CI) (CA INDEX NAME)





Absolute stereochemistry.



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 30 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:390408 CAPLUS
DN 131:45047
TI Preparation of sialyl Lewisx and sialyl Lewisx glyco-mimetics as
selectin inhibitors
IN Anderson, Mark B.; Kobayashi, Yoshiyuki; Itoh, Kazuhiro; Holme, Kevin R.;
Cui, Jingrong; Fugedi, Peter; Peto, Csaba F.; Wang, Li; Vazir, Harish
PA Glycomed Incorporated, USA; Sankyo Co., Ltd.
SO PCT Int. Appl., 184 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9929705	A2	19990617	WO 1998-US25783	19981204
	WO 9929705	A3	19990819		
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,				
	KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,				
	MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,				
	TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,				
	FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,				
	CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9918042	A	19990628	AU 1999-18042	19981204
PRAI	US 1997-67971P	P	19971208		
	WO 1998-US25783	W	19981204		
OS	MARPAT 131:45047				
GI					



AB The present invention provides a series of compds. in the form of chemical and physiol. stable glyco-mimics or glyco-epitopes I-III and $\text{MO}_2\text{C}(\text{CH}_2)_n\text{NHC}(\text{O})\text{YG}$ wherein W is a covalent bond, $-\text{C}(=\text{O})-$, $-\text{C}(=\text{O})-\text{CH}_2-$, $-\text{C}(=\text{O})-\text{CH}_2-\text{CH}_2-$, $-\text{C}(=\text{O})-\text{CH}=\text{CH}-$, $-\text{C}(=\text{O})-\text{CH}(\text{-NHAc})-\text{CH}_2-$, $-\text{C}(=\text{O})-\text{CH}_2-\text{CHOH}-$, $-\text{C}(=\text{O})-\text{CH}(\text{-NH-C}(=\text{O})-\text{O-t-Bu})-\text{CH}_2-$, $-\text{C}(=\text{S})-$, $-\text{C}(=\text{S})-\text{S}-$, $-\text{C}(=\text{S})-\text{S}-\text{CH}_2-$, $-\text{C}(=\text{S})-\text{CH}_2-\text{CH}_2-$, $-\text{C}(=\text{S})-\text{NH}-$, $-\text{CH}_2-\text{CH}_2-\text{O}-$, $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{CH}_2-$, $-\text{CH}_2-\text{CH}(\text{CH}_2\text{OH})-\text{CH}_2-$, $-\text{CH}_2-\text{C}(=\text{CH}_2)-\text{CH}_2-$; X is $-\text{NR}_3-$, $-\text{C}(\text{R}_8)_2-$, $-\text{NR}_8-$, CH-S-sialic acid , CH-O-sialic acid , $-\text{O}-$ or $-\text{S}-$; Y is a covalent bond, $-(\text{CH}_2)_n-$, $-\text{CH}_2-\text{NH-C}(=\text{O})-$, or $-\text{NH-C}(=\text{O})-$; R_1 - R_9 are independently selected from the group consisting of $-\text{H}$, $-\text{OH}$, alkyl, $-\text{CO}_2\text{M}$, $-\text{CH}_2-\text{CO}_2\text{M}$, $-\text{CO}_2\text{Me}$, $-\text{CH}_2-\text{CO}_2\text{Me}$, $-\text{CO}_2\text{Et}$, $-\text{CH}_2\text{CO}_2\text{Et}$, $-\text{CH}_2-\text{CH}=\text{CH}-\text{CO}_2\text{M}$, $-\text{CH}_2-\text{CH}=\text{CH}-\text{CO}_2\text{Me}$, $-\text{CH}_2-\text{CH}=\text{CH}-\text{CO}_2\text{Et}$, $-\text{OSO}_3\text{M}$, $-\text{CH}_2-\text{OSO}_3\text{M}$, $-\text{OPO}_3\text{M}_2$, $-\text{CH}_2-\text{OPO}_3\text{M}_2$ with the proviso that at least one of R_1 - R_9 is not $-\text{H}$ or $-\text{OH}$; G is heterocycle; M is a metal, n is 1-3, that serve to functionally mimic the active features of biol. important oligosaccharides, such as but not limited to sialyl Lewisx and sialyl Lewisy. These structural glyco-mimetics are useful in the treatment of acute and chronic diseases and asthma. These compds. also are useful in the treatment of other selectin-mediated disorders, such as inflammation, cancer, diabetes, obesity, lung vasculitis, cardiac injury, reperfusion injuries, thrombosis, tissue rejection, arthritis, inflammatory bowel disease and pulmonary inflammation. Thus, carboxymethyl-piperidine-N-isopropenyl-C-fucoside IV was prepared and tested as selectin inhibitor ($\text{IC}_{50} > 2500 \mu\text{M}$).


IT 227460-65-3P 227460-71-1P 227460-73-3P
227460-80-2P 227460-82-4P 227460-86-8P
227460-87-9P 227461-37-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of sialyl Lewisx and sialyl Lewisy glyco-mimetics as selectin inhibitors)

RN 227460-65-3 CAPLUS

CN Butanoic acid, 4-[(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)amino]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 227460-71-1 CAPLUS

CN Butanoic acid, 4-[[[(3,7-anhydro-2-deoxy-D-glycero-L-gluc-octonoyl)amino]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 227460-73-3 CAPLUS

CN Butanoic acid, 4-[[[(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)amino]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 227460-80-2 CAPLUS

CN β -Alanine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)glycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 227460-82-4 CAPLUS

CN β -Alanine, N-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)glycyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 227460-86-8 CAPLUS

CN β -Alanine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl) - (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 227460-87-9 CAPLUS

CN β -Alanine, N-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl) - (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 227461-37-2 CAPLUS


CN Cyclohexanecarboxylic acid, 4-[[[(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)amino]methyl]-, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 31 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1999:67133 CAPLUS
 DN 130:182670
 TI An access to glycoconjugate libraries through multicomponent reactions
 AU Lockhoff, Oswald
 CS Bayer AG, Central Research, ZF-WF Q18, Leverkusen, D-51368, Germany
 SO Angewandte Chemie, International Edition (1999), Volume Date 1998, 37(24),
 3436-3439
 CODEN: ACIEF5; ISSN: 1433-7851
 PB Wiley-VCH Verlag GmbH
 DT Journal
 LA English
 AB A multicomponent condensation (MCC)-based combinatorial synthesis of
 glycoconjugate libraries using appropriate carbohydrate derivs. having
 aldehyde, amino, carboxylic acid and isocyanide groups with solid-phase
 Ugi reactions is discussed.
 IT 204069-02-3P 204069-07-8P 204069-19-2P
 204069-21-6P 204069-23-8P 204069-25-0P
 204069-33-0P 220689-70-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (multicomponent condensation combinatorial synthesis of glycoconjugate
 libraries through Ugi reactions)
 RN 204069-02-3 CAPLUS
 CN D-erythro-L-galacto-Octonamide, 2-[acetyl[(4-methoxyphenyl)methyl]amino]-
 3,7-anhydro-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 204069-07-8 CAPLUS
 CN D-erythro-L-talo-Octonamide, 2-[acetyl[(4-methoxyphenyl)methyl]amino]-3,7-

anhydro-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204069-19-2 CAPLUS

CN D-erythro-L-talo-Octonamide, 2-[acetyl[[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]amino]-3,7-anhydro-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204069-21-6 CAPLUS

CN D-erythro-L-galacto-Octonamide, 2-[acetyl[[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]amino]-3,7-anhydro-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204069-23-8 CAPLUS

CN D-erythro-L-galacto-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl][(4-methoxyphenyl)methyl]amino]-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204069-25-0 CAPLUS

CN D-erythro-L-talo-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl][(4-methoxyphenyl)methyl]amino]-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204069-33-0 CAPLUS

CN D-glycero-D-gulo-Octonamide, 2-[acetyl[(4-methoxyphenyl)methyl]amino]-3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-N-[[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]-, (2ξ)-(9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 220689-70-3 CAPLUS


CN D-glycero-D-gulo-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl][[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]amino]-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-, (2ξ)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 32 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:756365 CAPLUS
DN 130:95830
TI Automated, Solid-Phase Synthesis of C-Neoglycopeptides: Coupling of
Glycosyl Derivatives to Resin-Bound Peptides
AU Kutterer, Kristina M. K.; Barnes, Michael L.; Arya, Prabhat
CS Steacie Institute for Molecular Sciences, National Research Council of
Canada, Ottawa, ON, K1A 0R6, Can.
SO Journal of Combinatorial Chemistry (1999), 1(1), 28-31
CODEN: JCCHFF; ISSN: 1520-4766
PB American Chemical Society
DT Journal
LA English
GI



AB A fully automated solid-phase synthesis of C-neoglycopeptides has been developed using a convergent strategy. In this approach, C-glycoside derivs. I and II were coupled to resin-bound peptides using a peptide synthesizer. An advantage of the convergent approach is the ability to introduce multiple glycoside units late in the synthesis. The approach presented is highly versatile and efficient and could be used for building C-neoglycopeptide libraries. In this study, neoglycopeptides Fmoc-Lys(R)-Gly2-NH2 (R = acyl group from I, n = 1; R = acyl group from II, n = 3) were obtained from the coupling of C-glycoside derivs. I and II to the free side chain amino group of short lysine-containing peptides. A similar approach was developed for the synthesis of bivalent neoglycopeptides Fmoc-Lys(R)-Gly-Ala-Gly-Lys(R)-Gly2-NH2 in an automated manner. The successful syntheses of these C-neoglycopeptides are the first examples of coupling of C-glycosyl carboxyl derivs. to the side chain amino groups of resin-bound peptides.

IT 193156-93-3


RL: RCT (Reactant); RACT (Reactant or reagent)

(automated, solid-phase synthesis of C-neoglycopeptides via coupling of glycosyl derivs. to resin-bound peptide side chains)

RN 193156-93-3 CAPLUS

CN Glycine, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluc-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 219543-11-0P 219543-12-1P 219543-13-2P

219543-14-3P


RL: SPN (Synthetic preparation); PREP (Preparation)

(automated, solid-phase synthesis of C-neoglycopeptides via coupling of glycosyl derivs. to resin-bound peptide side chains)

RN 219543-11-0 CAPLUS

CN Glycinamide, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluc-octonoyl)-L-lysyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219543-12-1 CAPLUS

CN Glycinamide, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-N6-[N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)glycyl]-L-lysylglycylglycyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 219543-13-2 CAPLUS

CN Glycinamide, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycyl-L-alanyl-L-lysyl-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 219543-14-3 CAPLUS


CN Glycinamide, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-N6-[N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)glycyl]-L-lysylglycyl-L-alanylglycyl-N6-[N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)glycyl]-L-lysylglycylglycyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




PAGE 2-A

OAc




PAGE 2-B



RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 33 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:630402 CAPLUS
DN 129:331035
TI Synthesis of sialyl Lewis X mimetics using the Ugi four-component reaction
AU Tsai, Chung-Ying; Park, William K. C.; Weitz-Schmidt, Gabriele; Ernst, Beat; Wong, Chi-Huey
CS Department Chemistry, The Scripps Research Institute, La Jolla, CA, 92037, USA
SO Bioorganic & Medicinal Chemistry Letters (1998), 8(17), 2333-2338
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
GI



I

AB Application of the Ugi four-component condensation to rapidly synthesize a library of glycopeptide mimics, e.g. I [R = Me, CF₃, (CH₂)₄Me, (CH₂)₁₂Me, CH:CHCH:CHMe, Ph, 1-naphthylmethyl, 2-naphthylmethyl, 4-PhC₆H₄,

1-fluorenyl, 9-fluorenylmethyl] of the tetrasaccharide SLex as inhibitors of E- and P-selectin, and to study the effect of varied functionality in mimics on the inhibition is described.

IT 215163-38-5P 215163-39-6P 215163-40-9P
 215163-41-0P 215163-42-1P 215163-43-2P
 215163-44-3P 215163-45-4P 215163-46-5P
 215163-47-6P 215163-48-7P 215163-49-8P
 215163-51-2P 215163-66-9P 215163-67-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(use of Ugi four-component reaction in prepn. of sialyl Lewis X glycopeptide mimics as selectin inhibitors)

RN 215163-38-5 CAPLUS

CN Glycine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-N-[(1S)-1,3-dicarboxypropyl]-L-alanyl-, 2-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 215163-39-6 CAPLUS

CN Glycine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-N-[(1S)-1,3-dicarboxypropyl]-D-alanyl-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 215163-40-9 CAPLUS


CN Glycine, N-(3,7-anhydro-2-deoxy-8-O-5,8,11,14-tetraoxahexadec-1-yl-D-glycero-D-talo-octonoyl)-N-[(1S)-1,3-dicarboxypropyl]-L-alanyl-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 215163-41-0 CAPLUS
CN Glycine, N-(3,7-anhydro-2-deoxy-8-O-5,8,11,14-tetraoxahexadec-1-yl-D-glycero-D-talo-octonoyl)-N-[(1S)-1,3-dicarboxypropyl]-D-alanyl-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






RN 215163-42-1 CAPLUS
 CN Glycine, N-[3,7-anhydro-2-deoxy-8-O-[3-[4-(4-phenoxyphenoxy)phenyl]propyl]-D-glycero-D-talo-octonoyl]-N-[(1S)-1,3-dicarboxypropyl]-L-alanyl-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215163-43-2 CAPLUS
 CN Glycine, N-[3,7-anhydro-2-deoxy-8-O-[3-[4-(4-phenoxyphenoxy)phenyl]propyl]-D-glycero-D-talo-octonoyl]-N-[(1S)-1,3-dicarboxypropyl]-D-alanyl-, 2-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



—OMe


RN 215163-44-3 CAPLUS
 CN Glycine, N-(3,7-anhydro-2-deoxy-8-O-phenyl-D-glycero-D-talo-octonoyl)-N-
 [(1S)-1,3-dicarboxypropyl]-L-alanyl-, 2-methyl ester (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 215163-45-4 CAPLUS
 CN Glycine, N-(3,7-anhydro-2-deoxy-8-O-phenyl-D-glycero-D-talo-octonoyl)-N-
 [(1S)-1,3-dicarboxypropyl]-D-alanyl-, 2-methyl ester (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 215163-46-5 CAPLUS

CN L-Glutamic acid, N-(3,7-anhydro-2-deoxy-8-O-phenyl-D-glycero-D-talo-octonoyl)-N-[(1S)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]ethyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 215163-47-6 CAPLUS

CN L-Glutamic acid, N-(3,7-anhydro-2-deoxy-8-O-phenyl-D-glycero-D-talo-octonoyl)-N-[(1R)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]ethyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 215163-48-7 CAPLUS

CN L-Glutamic acid, N-(3,7-anhydro-2-deoxy-8-O-phenyl-D-glycero-D-talo-octonoyl)-N-[(1S)-2-[(1,1-dimethylethyl)amino]-1-methyl-2-oxoethyl]- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 215163-49-8 CAPLUS

CN L-Glutamic acid, N-(3,7-anhydro-2-deoxy-8-O-phenyl-D-glycero-D-talo-octonoyl)-N-[(1R)-2-[(1,1-dimethylethyl)amino]-1-methyl-2-oxoethyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 215163-51-2 CAPLUS

CN Glycine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-N-[(1S)-1,3-dicarboxypropyl]-L- α -glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 215163-66-9 CAPLUS


CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-5,8,11,14-tetraoxahexadec-1-yl-D-glycero-D-talo-octonoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 215163-67-0 CAPLUS
 CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-[3-[4-(4-phenoxyphenoxy)phenyl]propyl]-D-glycero-D-talo-octonoyl]- (9CI). (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




IT 215163-31-8P 215163-32-9P 215163-33-0P
 215163-34-1P 215163-35-2P 215163-36-3P
 215163-37-4P 215163-64-7P 215163-65-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (use of Ugi four-component reaction in prepn. of sialyl Lewis
 X glycopeptide mimics as selectin inhibitors)
 RN 215163-31-8 CAPLUS
 CN Glycine, N-[3,7-anhydro-2-deoxy-4,5,6-tris-O-(phenylmethyl)-D-glycero-D-
 talo-octonoyl]-N-[(1S)-4-oxo-4-(phenylmethoxy)-1-
 [(phenylmethoxy)carbonyl]butyl]-L-alanyl-, methyl ester (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 215163-32-9 CAPLUS
 CN Glycine, N-[3,7-anhydro-2-deoxy-4,5,6-tris-O-(phenylmethyl)-8-O-5,8,11,14-
 tetraoxahexadec-1-yl]-D-glycero-D-talo-octonoyl]-N-[(1S)-4-oxo-4-
 (phenylmethoxy)-1-[(phenylmethoxy)carbonyl]butyl]-L-alanyl-, methyl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 215163-33-0 CAPLUS

215183 33-0 CAS:335
CN Glycine, N-[3,7-anhydro-2-deoxy-8-O-[3-[4-(4-phenoxyphenoxy)phenyl]propyl]-
4,5,6-tris-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-N-[(1S)-4-oxo-4-
(phenylmethoxy)-1-[(phenylmethoxy)carbonyl]butyl]-L-alanyl-, methyl ester
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 215163-34-1 CAPLUS

CN Glycero, N-[3,7-anhydro-2-deoxy-8-O-methyl-4,5,6-tris-O-(phenylmethyl)-D-
 glycerol-D-talo-ononoyl]-N-[(1S)-4-oxo-4-(phenylmethoxy)-1-
 [(phenylmethoxy)carbonyl]butyl]-L-alanyl-, methyl ester (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 215163-35-2 CAPLUS

CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-phenyl-4,5,6-tris-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-N-[1-methyl-2-oxo-2-[(2-phenylethyl)amino]ethyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 215163-36-3 CAPLUS


CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-phenyl-4,5,6-tris-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-N-[2-[(1,1-dimethylethyl)amino]-1-methyl-2-oxoethyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 215163-37-4 CAPLUS
 CN Glycine, N-[3,7-anhydro-2-deoxy-4,5,6-tris-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-N-[(1S)-4-oxo-4-(phenylmethoxy)-1-[(phenylmethoxy)carbonyl]butyl]-L- α -glutamyl-, 2-methyl 1-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 215163-64-7 CAPLUS
 CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-4,5,6-tris-O-(phenylmethyl)-8-O-5,8,11,14-tetraoxahexadec-1-yl-D-glycero-D-talo-octonoyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B




RN 215163-65-8 CAPLUS
 CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-[3-[4-(4-phenoxyphenoxy)phenyl]propyl]-4,5,6-tris-O-(phenylmethyl)-D-glycero-D-talo-


octonoyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



IT 215163-50-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (use of Ugi four-component reaction in prepn. of sialyl Lewis
 X glycopeptide mimics as selectin inhibitors)
 RN 215163-50-1 CAPLUS
 CN Glycine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-N-[(1S)-1,3-
 dicarboxypropyl]-L-α-glutamyl-, 2-methyl ester (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 34 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1998:348137 CAPLUS
 DN 129:81942
 TI Diversity of C-linked neoglycopeptides for the exploration of
 subsite-assisted carbohydrate binding interactions
 AU Arya, Prabhat; Kutterer, Kristina M. K.; Qin, Huiping; Roby, Johanne;
 Barnes, Michael L.; Kim, Jin M.; Roy, Rene
 CS Steacie Institute for Molecular Sciences, National Research Council of
 Canada, Ottawa, ON, K1A 0R6, Can.
 SO Bioorganic & Medicinal Chemistry Letters (1998), 8(10), 1127-1132
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 AB Diversity of α -galactose based C-linked neoglycopeptides has been
 developed to explore the importance of subsite-assisted carbohydrate
 binding interactions. Deprotected C-linked neoglycopeptides, e.g.,
 Ac-Lys(COCH₂R)-Gly-NH₂ (R = 1-deoxy-C1- α -D-galacto-pyranosyl) (1b)
 and (S)-AcNHCH[(CH₂)₄N[(CH₂)₂R]2]CO-Gly-NH₂ (same R) (2b), were
 synthesized and tested in competitive inhibition assays using a model
 enzyme-linked lectin (e.g., Maclura pomifera). Compound 2b, with two
 α -galactoside units on the side chain of the lysine residue of the
 dipeptide backbone, exhibited a remarkable effect with a 2.82-fold
 increase in its inhibitory properties (IC₅₀ 1.48 mM) in comparison to 1b
 (IC₅₀ 4.18 mM).
 IT 209265-32-7P 209265-34-9P 209265-35-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); BIOL (Biological
 study); PREP (Preparation)
 (diversity of C-linked neoglycopeptides for exploration of
 subsite-assisted carbohydrate binding interactions)
 RN 209265-32-7 CAPLUS
 CN Glycinamide, N2-acetyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-
 L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209265-34-9 CAPLUS
 CN Glycinamide, N2-acetyl-N6-[N-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-
 octonoyl)-N-(2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-
 yl)glycyl]-L-lysyl-N,N-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209265-35-0 CAPLUS


CN Glycinamide, N2-acetyl-N6- [N3,N5-bis [N- (3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl) -L-alanylglycyl] -3,5-diaminobenzoyl] -L-lysyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 35 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1998:293511 CAPLUS

DN 129:4814

TI Preparation of sialyl Lewis X mimetics as E-selectrin inhibitors

IN Wong, Chi-huey; Moris-Varas, Francisco; Lin, Chun-cheng; Marron, Thomas G.; Woltering, Thomas; Weitz-Shmidt, Gabriele; Jablonowski, Jill

PA Novartis A.-G., Switz.; Scripps Research Institute

SO PCT Int. Appl., 53 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9818805	A2	19980507	WO 1997-EP5909	19971027
	WO 9818805	A3	20030417		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 5830871	A	19981103	US 1996-744744	19961028
	US 5837862	A	19981117	US 1996-764315	19961212
	AU 9853137	A	19980522	AU 1998-53137	19971027
PRAI	US 1996-744744	A	19961028		
	US 1996-764315	A	19961212		
	US 1997-896452	A	19970718		
	WO 1997-EP5909	W	19971027		
OS	MARPAT 129:4814				
GI					



AB Sialyl Lewis X mimetics which mimic the inhibition of selectin-mediated cellular adhesion by sialyl Lewis X having a core of formula [(I); R = Me, OH, carboxylate-containing sugar residue; Y = alkene; R1 = OH, NH₂, amide, amino acid] were prepared. Thus, compds. such as II were prepared and tested for ability to block the adhesion of HL-60 cells to immobilized sol-E-selectin. Compds. of formula I showed inhibition at 3mM of 70-80%, or IC₅₀ values from 0.1-0.2mM.


IT 186532-53-6P 186532-55-8P 186532-57-0P
194980-12-6P 194980-14-8P 204458-84-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of sialyl Lewis X mimetics as E-selectin inhibitors)

RN 186532-53-6 CAPLUS

CN Glycine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186532-55-8 CAPLUS

CN L-Tyrosine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186532-57-0 CAPLUS

CN L-Glutamic acid, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 194980-12-6 CAPLUS


CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-hexadecyl-D-glycero-D-talo-octonoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 194980-14-8 CAPLUS
 CN Benzoic acid, 3-[[[3,7-anhydro-2-deoxy-6-O-hexadecyl-D-glycero-D-talo-
 octonoyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 204458-84-4 CAPLUS
 CN β -D-Talopyranoside, methyl 2-[[[3,7-anhydro-2-deoxy-D-glycero-D-talo-
 octonoyl]amino]-3-O-(carboxymethyl)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 194980-10-4 194980-11-5 204458-91-3
 204458-92-4 207387-06-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of sialyl Lewis X mimetics as E-selectrin inhibitors)
 RN 194980-10-4 CAPLUS
 CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-
 D-glycero-D-talo-octonoyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 194980-11-5 CAPLUS
 CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-hexadecyl-4,5,6-tris-O-
 (phenylmethyl)-D-glycero-D-talo-octonoyl]-, bis(phenylmethyl) ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 204458-91-3 CAPLUS

CN Glycine, N-[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204458-92-4 CAPLUS

CN L-Tyrosine, N-[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 207387-06-2 CAPLUS


CN β -D-Galactopyranoside, methyl 2-[[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]amino]-3-O-(carboxymethyl)-2-deoxy-4,6-O-[(S)-phenylmethylen]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 36 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1998:257568 CAPLUS
 DN 128:321842
 TI Synthesis of benzylated (R)- and (S)-aminoethyl-C- α -D-mannosides as conformationally restricted building blocks for the preparation of E- and P-selectin antagonists
 AU Roche, Didier; Banteli, Rolf; Winkler, Tammo; Casset, Florence; Ernst, Beat
 CS Novartis Pharma Corp., East Hanover, NJ, 07936, USA
 SO Tetrahedron Letters (1998), 39(17), 2545-2548
 CODEN: TELEAY; ISSN: 0040-4039
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 AB A straightforward synthesis for (R)- and (S)-aminoethyl-C- α -D-mannosides has been developed. The conformationally restricted mannosides serve as building blocks for the synthesis of a new class of selectin antagonists of type A.
 IT 207107-97-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of benzylated (R)- and (S)-aminoethyl-C-mannosides as conformationally restricted building blocks for the prepn. of E- and P-selectin antagonists)
 RN 207107-97-9 CAPLUS
 CN D-erythro-L-allo-Octonamide, 3,7-anhydro-2-deoxy-2-methyl-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 37 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1998:184112 CAPLUS
 DN 128:230687
 TI Preparation of glycoconjugate amino acids for use as a
 combinatorial library for receptor-site screening
 IN Lockhoff, Oswald
 PA Bayer A.-G., Germany
 SO Ger. Offen., 28 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19636538	A1	19980312	DE 1996-19636538	19960909
	EP 832898	A2	19980401	EP 1997-114805	19970827
	EP 832898	A3	19980429		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CA 2214728	A1	19980309	CA 1997-2214728	19970905
	JP 10101634	A	19980421	JP 1997-259273	19970908
PRAI	DE 1996-19636538	A	19960909		
OS	CASREACT 128:230687; MARPAT 128:230687				
GI					



AB Using four-component reactions, title compds. R2CONR1CHRCOXR3 [(I); R = R1 = (same or different) alkyl, cycloalkyl, aralkyl, aromatic heterocycle, (substituted) tetrahydro-furanyl, (substituted) tetrahydro-pyranyl; R2 = H, R1; R3 = H, R1; X = O, NH, N(alkyl), S] were prepared as possible screening reagents for cellular receptor sites (no data), from reaction mixts. of an aldehyde, an amine, a carbon-acid, and an isonitrile, any of which could be a carbohydrate. Thus, 2,6-anhydro-3,4,5,7-tetra-O-benzyl-D-glycero-D-gulo-heptose, MeO-C6H4-4-CH2NH2, CH3CO2H, and c-C6H11NC were reacted to give II (65% over all yield, as a mixture of diastereomers).

IT 204069-02-3P 204069-07-8P 204069-19-2P
 204069-21-6P 204069-23-8P 204069-25-0P
 204069-33-0P 204069-35-2P 204069-37-4P
 204069-39-6P 204069-40-9P 204069-44-3P
 204069-48-7P


RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of glycoconjugate amino acids for use as a combinatorial library for receptor site screening)

RN 204069-02-3 CAPLUS

CN D-erythro-L-galacto-Octonamide, 2-[acetyl[(4-methoxyphenyl)methyl]amino]-3,7-anhydro-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204069-07-8 CAPLUS

CN D-erythro-L-talo-Octonamide, 2-[acetyl[(4-methoxyphenyl)methyl]amino]-3,7-anhydro-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204069-19-2 CAPLUS

CN D-erythro-L-talo-Octonamide, 2-[acetyl[(2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl)methyl]amino]-3,7-anhydro-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204069-21-6 CAPLUS

CN D-erythro-L-galacto-Octonamide, 2-[acetyl[[2,3,4,6-tetrakis-O-(phenylmethyl)- β -D-glucopyranosyl]methyl]amino]-3,7-anhydro-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204069-23-8 CAPLUS


CN D-erythro-L-galacto-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl] [(4-methoxyphenyl)methyl]amino]-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 204069-25-0 CAPLUS
 CN D-erythro-L-talo-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl][(4-methoxyphenyl)methyl]amino]-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204069-33-0 CAPLUS
 CN D-glycero-D-gulo-Octonamide, 2-[acetyl[(4-methoxyphenyl)methyl]amino]-3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-N-[[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]-, (2ξ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 204069-35-2 CAPLUS

CN D-erythro-L-talo-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl][[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]amino]-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

RN 204069-37-4 CAPLUS

CN D-erythro-L-galacto-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl][2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosylmethyl]amino]-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 204069-39-6 CAPLUS

CN D-glycero-D-gulo-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl][(4-methoxyphenyl)methyl]amino]-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-N-[[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosylmethyl]-, (2ξ) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204069-40-9 CAPLUS

CN D-glycero-D-gulo-Octonamide, 2-[acetyl[[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]amino]-3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-N-[[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]-, (2ξ)-(9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 204069-44-3 CAPLUS

CN D-glycero-D-gulo-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl] [[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]amino]-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-N-[[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]methyl]-, (2ξ)-(9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 204069-48-7 CAPLUS

CN D-glycero-D-gulo-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl][[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]amino]-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-N-[[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-galactopyranosyl]methyl]-, (2ξ)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT 204069-46-5

RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of glycoconjugate amino acids for use as a
 combinatorial library for receptor site screening)

RN 204069-46-5 CAPLUS

CN D-glycero-D-gulo-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-
 O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl][[2,3,4,6-tetrakis-O-
 (phenylmethyl)-β-D-glucopyranosyl]methyl]amino]-N-1-cyclohexen-1-yl-2-
 deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-, (2ξ)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



L8 ANSWER 38 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1998:163599 CAPLUS
 DN 128:230633
 TI Preparation of sialyl Lewis x mimetics as E-selectin inhibitors
 IN Wong, Chi-Huey; Lin, Chun-Cheng; Woltering, Thomas J.; Marron, Thomas G.;
 Moris-Varas, Francisco; Jablonowski, Jill; Weitz-Schmidt, Gabriele
 PA Novartis A.-G., Switz.; Scripps Research Institute; Wong, Chi-Huey; Lin,
 Chun-Cheng; Woltering, Thomas J.; Marron, Thomas G.; Moris-Varas,
 Francisco; Jablonowski, Jill; Weitz-Schmidt, Gabriele
 SO PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9808854	A2	19980305	WO 1997-EP4649	19970826
	WO 9808854	A3	19980820		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5830871	A	19981103	US 1996-744744	19961028

US 5837862	A	19981117	US 1996-764315	19961212
AU 9747004	A	19980319	AU 1997-47004	19970826
PRAI US 1996-24556P	P	19960826		
US 1996-744744	A	19961028		
US 1996-764315	A	19961212		
WO 1997-EP4649	W	19970826		
OS MARPAT 128:230633				
GI				




AB Sialyl Lewis X mimetics which mimic the inhibition of selectin-mediated cellular adhesion by sialyl Lewis X having a core of formula I (R₁ = Me, OH, carboxylate-containing sugar residue; Y = alkylene; R₂ = hydroxy, amine, amide, amino acid) were prepared. Thus, II was prepared and tested for ability to block the adhesion of HL-60 cells to immobilized sol-E-selectin (IC₅₀ = 0.1-0.2 mM).

IT 186532-53-6P 186532-55-8P 186532-57-0P
194980-12-6P 204458-84-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of sialyl Lewis x mimetics as E-selectin inhibitors)

RN 186532-53-6 CAPLUS

CN Glycine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186532-55-8 CAPLUS

CN L-Tyrosine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186532-57-0 CAPLUS

CN L-Glutamic acid, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 194980-12-6 CAPLUS

CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-hexadecyl-D-glycero-D-talo-octonoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204458-84-4 CAPLUS

CN β -D-Talopyranoside, methyl 2-[(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)amino]-3-O-(carboxymethyl)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 194980-11-5 194980-14-8 204458-91-3

204458-92-4 204458-93-5


RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of sialyl Lewis x mimetics as E-selectin inhibitors)

RN 194980-11-5 CAPLUS

CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-hexadecyl-4,5,6-tris-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-, bis(phenylmethyl) ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 194980-14-8 CAPLUS

CN Benzoic acid, 3-[[3,7-anhydro-2-deoxy-6-O-hexadecyl-D-glycero-D-talo-octonoyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204458-91-3 CAPLUS

CN Glycine, N-[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204458-92-4 CAPLUS

CN L-Tyrosine, N-[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204458-93-5 CAPLUS

CN L-Tyrosine, N-[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-O-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 39 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:667131 CAPLUS

DN 127:229196

TI Small Molecules as Structural and Functional Mimics of Sialyl Lewis X in Selectin Inhibition: A Remarkable Enhancement of Inhibition by Additional Negative Charge and/or Hydrophobic Group

AU Wong, Chi-Huey; Moris-Varas, Francisco; Hung, Shang-Cheng; Marron, Thomas G.; Lin, Chun-Cheng; Gong, Ke Wei; Weitz-Schmidt, Gabriele

CS Department of Chemistry, Scripps Research Institute, La Jolla, CA, 92037, USA

SO Journal of the American Chemical Society (1997), 119(35), 8152-8158
CODEN: JACSAT; ISSN: 0002-7863

PB American Chemical Society

DT Journal

LA English

OS CASREACT 127:229196

AB Several sialyl Lewis X (SLex) mimics that contain the essential functional groups for receptor interaction and a neg. charge or a hydrophobic group have been developed as inhibitors of E-, P-, and L-selectins. Some of the mimics exhibit selectin inhibition activities 103-104-fold more potent than does the natural ligand tetrasaccharide, with IC50 in the low micromolar to high nanomolar range. The syntheses of these mimics are relatively simple, using TMSOTf-Ac2O mediated C-glycosylation with concurrent selective deprotection of the primary benzyl group and enzymic aldol addition reactions as key steps.

IT 194980-10-4P 194980-11-5P 194980-13-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)

(intermediate; small mols. as structural and functional mimics of
sialyl Lewis x in selectin inhibition in relation to addnl. neg. charge
and/or hydrophobic Group)

RN 194980-10-4 CAPLUS

CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-
D-glycero-D-talo-octonoyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 194980-11-5 CAPLUS

CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-hexadecyl-4,5,6-tris-O-
(phenylmethyl)-D-glycero-D-talo-octonoyl]-, bis(phenylmethyl) ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 194980-13-7 CAPLUS


CN Benzoic acid, 3-[[3,7-anhydro-2-deoxy-6-O-hexadecyl-4,5,6-tris-O-
(phenylmethyl)-D-glycero-D-talo-octonoyl]amino]-, ethyl ester (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




IT 865714-47-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (mimics; small mols. as structural and functional mimics of sialyl
 Lewis x in selectin inhibition in relation to addnl. neg. charge and/or
 hydrophobic Group)
 RN 865714-47-2 CAPLUS
 CN Benzoic acid, 3-[[3,7-anhydro-2-deoxy-8-O-hexadecyl-4,5,6-tris-O-
 (phenylmethyl)-D-glycero-D-talo-octonoyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 186532-57-0P 194980-12-6P 194980-14-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (small mols. as structural and functional mimics of sialyl Lewis x in
 selectin inhibition in relation to addnl. neg. charge and/or
 hydrophobic Group)
 RN 186532-57-0 CAPLUS
 CN L-Glutamic acid, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 194980-12-6 CAPLUS
 CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-hexadecyl-D-glycero-D-talo-
 octonoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 194980-14-8 CAPLUS

CN Benzoic acid, 3-[[3,7-anhydro-2-deoxy-6-O-hexadecyl-D-glycero-D-talo-octonoyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 40 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:528274 CAPLUS

DN 127:109119

TI Stereoselective Synthesis of C-Amino-Substituted D-Mannopyranosides. Easy Preparation of Novel Inhibitors for Mannosidases

AU Lopez-Herrera, Fidel J.; Sarabia-Garcia, Francisco; Heras-Lopez, A.; Pino-Gonzalez, M. S.

CS Departamento de Bioquímica Biología Molecular y Química Orgánica Facultad de Ciencias, Universidad de Málaga, Málaga, 29071, Spain

SO Journal of Organic Chemistry (1997), 62(17), 6056-6059


CODEN: JOCEAH; ISSN: 0022-3263

PB American Chemical Society

DT Journal

LA English

GI



AB Title mannopyranosides, e.g. I, were prepared via condensation of 2,3:4,6-di-O-isopropylidene-D-mannopyranose with sulfur ylide Me₂SCHCONEt₂. I showed inhibitory activity against β-mannosidase (no data).

IT 191282-00-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(stereoselective prepn. of C-amino-substituted
mannopyranosides as mannosidase inhibitors)

RN 191282-00-5 CAPLUS

CN D-erythro-L-manno-Octonamide, 3,7-anhydro-N,N-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 191282-01-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(stereoselective prepn. of C-amino-substituted
mannopyranosides as mannosidase inhibitors)

RN 191282-01-6 CAPLUS

CN D-erythro-L-gluco-Octonamide, 2-amino-3,7-anhydro-2-deoxy-N,N-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 41 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:10067 CAPLUS

DN 126:144480

TI C-Mannose derivatives as potent mimics of sialyl Lewis X

AU Marron, Thomas G.; Woltering, Thomas J.; Weitz-Schmidt, Gabriele; Wong, Chi-Huey

CS Dep. Chem., Scripps Res. Inst., La Jolla, CA, 92037, USA

SO Tetrahedron Letters (1996), 37(50), 9037-9040


CODEN: TELEAY; ISSN: 0040-4039

PB Elsevier

DT Journal

LA English

GI



AB The prepn. of five sialyl Lewis X mimetics, e.g. I, was described. Mimic I showed activities five-fold better than sialyl Lewis X as selectin inhibitors.

IT 186532-53-6P 186532-55-8P 186532-57-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of C-mannoses as selectin inhibitors and potent mimics of sialyl Lewis X)

RN 186532-53-6 CAPLUS

CN Glycine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186532-55-8 CAPLUS

CN L-Tyrosine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186532-57-0 CAPLUS

CN L-Glutamic acid, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 42 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1996:650028 CAPLUS
DN 126:19208
TI Generation of C-Glycoside Peptide Ligands for Cell Surface Carbohydrate
Receptors Using a Four-Component Condensation on Solid Support
AU Sutherlin, Daniel P.; Stark, Todd M.; Hughes, Robert; Armstrong, Robert W.
CS Department of Chemistry and Biochemistry, University of California, Los
Angeles, CA, 90095, USA
SO Journal of Organic Chemistry (1996), 61(23), 8350-8354
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
AB The first synthesis of a C-glycopeptide combinatorial library on solid
support is described. The compds. are generated on the Rink resin through
an Ugi reaction, a multiple component condensation (MCC) that combines an
aldehyde, carboxylic acid, isocyanide and resin-bound amine to yield an
 α -acylamino amide. Utilizing C-glycosides as the aldehyde and/or
carboxylic acid input, compds. with a highly dense core of functionality
can be rapidly synthesized. These compds. can be used to study the
binding requirements of the cell surface carbohydrate receptors. This
method is demonstrated in the synthesis of eight diverse structures,
highlighting the general nature of this approach, and more specifically in
the synthesis of a 96 compound combinatorial library of C-glycopeptides
directed towards the receptors of the sialyl Lewis X blood group
determinant. Two protecting group strategies for the sugar hydroxyls have
been implemented, one employing benzyl ethers that can be cleanly removed
after the compds. cleavage from the resin, and the other using acetoxyl
groups that can be removed prior to cleavage. Both strategies yield
compds. of purity sufficient for high throughput screening.
IT 184100-14-9P 184100-34-3P 184100-35-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(generation of C-glycoside peptide ligands for cell surface
carbohydrate receptors using four-component condensation on solid
support)
RN 184100-14-9 CAPLUS
CN Glycine, N-[(2S)-4,8-anhydro-2-[(3,7-anhydro-2-deoxy-D-glycero-D-manno-
octonoyl)amino]-2,3-dideoxy-D-glycero-L-manno-nononoyl]-, methyl ester
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 184100-34-3 CAPLUS

CN Glycine, N-[(2S)-4,8-anhydro-2-[[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-D-glycero-L-manno-octonoyl]amino]-2,3-dideoxy-5,6,7,9-tetrakis-O-(phenylmethyl)-D-glycero-L-manno-nononoyl]-, methyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 184100-35-4 CAPLUS

CN Glycine, N-[(2S)-5,6,7,9-tetra-O-acetyl-4,8-anhydro-2,3-dideoxy-2-[(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-manno-octonoyl)amino]-D-glycero-L-manno-nononoyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 43 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1995:13473 CAPLUS

DN 122:56357
 TI On the synthesis of C-glycosyl compounds containing double bonds without
 the use of protecting groups
 AU Wulff, Guenter; Clarkson, Guy
 CS Inst. Org. Chem. Makromol. Chem., Heinrich-Heine Univ., Duesseldorf,
 40225, Germany
 SO Carbohydrate Research (1994), 257(1), 81-95
 CODEN: CRBRAT; ISSN: 0008-6215
 DT Journal
 LA English
 OS CASREACT 122:56357
 GI




AB A new range of C-glycosyl compds. carrying double bonds have been
 synthesized as potential monomers for the prepn. of
 polyvinyl-saccharides. The syntheses were performed without the use of
 protecting groups and mostly in water as solvent. The starting material
 was the easily accessible 5-β-D-glycopyranosyl-1,3-dimethylbarbituric
 acid sodium salt I (R = Na) (obtained from D-glucose and
 1,3-dimethylbarbituric acid in water). The alkylation reaction of I (R =
 Na) at C-5 of the barbiturate moiety was studied in detail. It works well
 with benzylic bromides in Me₂SO and with allylic or benzylic bromides by
 an ultrasound/phase transfer catalyst-promoted alkylation in water. The
 resulting 5,5-dialkylated barbiturates, e.g. I (R = CH₂C₆H₄-R₁, R₁ = H,
 CH:CH₂, CH₂CH₂Br; R = CH₂CR₂:CH₂, R₂ = H, Ph, CO₂Me), undergo an unusually
 facile and specific cleavage of the barbituric ring, losing the c-2
 carbonyl, to yield novel mols. with a diamide moiety.

IT 160055-68-5P 160055-69-6P 160055-70-9P
 160055-71-0P 160055-72-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)


RN 160055-68-5 CAPLUS
 CN Propanediamide, N,N'-dimethyl-2-(phenylmethyl)-2-(2,3,4,6-tetra-O-acetyl-
 β-D-glucopyranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160055-69-6 CAPLUS
 CN Propanediamide, 2-[(4-ethenylphenyl)methyl]-N,N'-dimethyl-2-(2,3,4,6-tetra-
 O-acetyl-β-D-glucopyranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160055-70-9 CAPLUS

CN Propanediamide, 5-[[4-(2-bromoethyl)phenyl]methyl]-N,N'-dimethyl-2-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160055-71-0 CAPLUS

CN Propanediamide, N,N'-dimethyl-2-(2-propenyl)-2-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160055-72-1 CAPLUS


CN Propanediamide, N,N'-dimethyl-2-(2-phenyl-2-propenyl)-2-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 44 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1983:139581 CAPLUS
 DN 98:139581
 TI Effect of aryl substituents on the kinetics of inactivation of glycosidases by glycosylmethylaryltriazenes: examination of the suicide nature of these inactivations
 AU Sinnott, Michael L.; Tzotzos, George T.; Marshall, Susan E.
 CS Dep. Org. Chem., Univ. Bristol, Bristol, BS8 1TS, UK
 SO Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999) (1982), (12), 1665-70
 CODEN: JCPKBH; ISSN: 0300-9580
 DT Journal
 LA English
 AB The inactivation of the Mg²⁺-free form of the gene lacZ β -galactosidase of Escherichia coli at 25° by various [(β -D-galactopyranosyl)methyl]aryltriazenes resembles the spontaneous, rather than the acid-catalyzed, decomposition of alkylaryltriazenes in that both the maximum 1st-order rate constant, and the 2nd-order rate constant, are governed by a neg. β lg value at pH 7.0 and 8.0. Less extensive measurements for the β -xylosidase of Penicillium wortmanni and [(β -D-xylopyranosyl)methyl]aryltriazenes give a similar result. Although the decomposition of the 2-(β -D-galactopyranosyl)ethyl compds. in aqueous solution is 5- to 10-fold faster than their lower homologs, β -galactosidase inactivation is 3- to 13-fold slower. [(β -D-Galactopyranosyl)methyl] (p-nitrophenyl) triazene does not inactivate the lectin, RCA ricin.
 IT 85011-71-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and dehydration and catalytic reduction of)
 RN 85011-71-8 CAPLUS
 CN D-glycero-L-manno-Octonamide, 3,7-anhydro-2-deoxy-, 4,5,6,8-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> dis hist

(FILE 'HOME' ENTERED AT 10:30:14 ON 30 JAN 2007)

FILE 'REGISTRY' ENTERED AT 10:30:29 ON 30 JAN 2007

L1 STRUCTURE UPLOADED

L2 23 S L1 SSS SAM

L3 450 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:31:58 ON 30 JAN 2007

L4 0 S L3 AND (GEM(A)DIFLUORO)

L5 0 S L3 AND DIFLUORO

L6 1 S L3 AND ZINC

L7 0 S L3 AND REFORMATSKY

L8 44 S L3 AND (PROCESS OR PREPARA?)

L9 2 S L8 AND CARBONYL

L10 0 S L8 AND (CARBONYL(W)ADDITION)